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Abstract 
Currently, chemotherapeutic research is using smart and specially engineered 
multifunctional nanocarriers for targeted nanomedicine for improved and promising cancer 
treatment. Mesoporous carbon nanomaterials (MCNs) have been widely regarded for this 
purpose owing to its multifunctional nature.  MCNs possess unique combinations of 
chemical and physical properties along with high surface area, high porosity, biocompatibility 
and high cellular uptake making them up-and-coming candidates in many areas of 
biomedical research such as drug delivery, tissue scaffolding, cellular sensors, etc. With a 
steady increment in the biomedical research centred on MCN as potential nanocarrier 
systems for chemotherapeutics, the need to determine the optimised conditions to 
synthesise MCN with the most desirable traits are that much more necessary. One of the 
critical factors that control the physical, chemical, electrical and mechanical behaviour of 
MCN is the carbonisation temperature. Carbonisation temperature determines the carbon 
content, carbon bonding, crystallinity, hydrophobicity, solubility, porosity which in turn 
influences their effectiveness. Although there have been studies on the characteristic 
differences in MCNs influenced by carbonisation temperature, however, the impact the 
carbonisation temperature makes in bio-application of MCN has not been reported so far. 
So, this PhD aims to study the influence of carbonisation temperature in MCNs and to 
investigate its behaviour in the biological environment for varied biological applications.  
 In the first part,  we prepared mesoporous carbon hollow spheres (MCHS) using 
resorcinol-formaldehyde polymer and silica hard-template in the one-pot synthesis process.  
We carbonised the polymer-silica matrix at different carbonisation temperatures (MCHS-T) 
and studied its changes in physical and chemical properties such as morphology, aqueous 
distribution, crystallinity, hydrophobicity, carbon content, surface area and porosity. We 
further investigated the loading capacity and release pattern of the various carbonised 
samples and their intracellular behaviour.  We observed that the delivery of therapeutic 
biomolecule in cancer cells varied depending on which temperature the nanocarriers were 
carbonised which led to different cytotoxicity.  With this study, we were able to find out the 
optimised temperature at which mesoporous carbon hollow spheres should be carbonised 
to achieve the best nanocarrier performance for the delivery of therapeutic protein in cancer 
therapy. 
 In the second part, we investigated the antioxidant property (free radical scavenging) 
mediated by the temperature of carbonisation of  MCHS-T. We found that MCHS-T is a great 
antioxidant agent which lowers the ROS levels in cells that are suffering from oxidative 
stress. We carbonised MCHS-T from temperatures 700-1300˚ C to find the optimised 
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temperature that elicits the maximum antioxidant property. We also demonstrated MCHS’s 
antioxidant property compared with other popular carbon nanoparticles in their pristine form. 
The extracellular ROS scavenging activity was analysed via (Electron paramagnetic 
resonance) EPR, and the intracellular antioxidant property was evaluated using flow 
cytometry (FACS), microplate reading and confocal imaging techniques.  
 In the third part, we tested the photothermal property (conversion of light into heat) and 
photothermal ablation capacity of MCHS-T when carbonised at various temperatures for a 
promising combination  (chemotherapy and photothermal) treatment. First, we tested the 
loading and delivery of 17AAG (a heat shock protein inhibitor) whose purpose is to make 
the cancer cells more susceptible to thermal damage. Then the cancer cells that internalised 
MCHS-T carrying 17AAG were irradiated with UV-light for a 3 min period, and the number 
of viable cells was checked to determine the effect of the combination therapy. 
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         Chapter 1 
Introduction 
1.1. The significance of the work 
 The development of specially designed and engineered nanoparticles possessing 
unique structures and properties has witnessed a massive surge in nano-biomedical 
research in recent years.    In particular, cancer research has substantially benefited 
from this development as it has opened gates to a newer chemotherapeutic approach 
than conventional methods that are usually associated with high-risk factors and side 
effects. Various nanoparticles systems have been synthesised such as polymer-based 
nanoparticles, lipid-based nanoparticles, micelles, quantum dots, nanofibers, 
magnetic nanoparticles, carbon-based nanoparticles, etc., to enhance the 
performance of drug molecules while reducing the risk of toxicity. Among them, 
carbon-based nanocarrier such as fullerenes, carbon nanotubes, carbon nano-horns, 
nanodiamonds, porous carbon and graphene has shown to be extremely beneficial in 
bio-medical applications for nanomedicine, drug delivery and bio-labelling, due to their 
distinct structures made up of uniquely hybridised carbons 2.  Carbon nanoparticles at 
present are standing at crossroads between proof of principle concept and established 
clinical candidates for therapeutic applications3. Carbon nanoparticles have distinct 
optical, thermal, mechanical and electrical properties along with inherent 
hydrophobicity, biocompatibility and their capacity to penetrate the cells and tissues 
which makes them suitable for different biological applications4, 5. Owing to the 
numerous benefits of carbon nanoparticles, researchers utilize  these multifunctional 
nanoparticles in three broad approaches for chemotherapeutic applications, 6, 7: 
1.  Nanocarrier systems:   Carbon nanocarrier systems (such as CNTs, graphene, 
fullerene, C dots, mesoporous carbon nanoparticles) possess some distinctive 
physicochemical and biological characteristics that make them suitable for diagnosis 
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and chemotherapeutic practices as they help overcome cellular barriers and enhance 
the intracellular concentration of drug candidates. Therapeutic bio-macromolecules 
such as nucleic acids, proteins, DNA, genes, are mainly benefited as they increase 
their bioavailability using both active and passive targeting strategies 8-11.  
2. ROS Scavenging Nanomedicines (Carbon-based antioxidants):   Carbon 
nanoparticles have demonstrated excellent antioxidant prowess owing to their high 
interaction with reactive oxygen species (ROS), the prime reason for various grave 
illnesses such as myocardial infarction, kidney failure, Rheumatoid Arthritis, 
Parkinson's, etc. Carbon nanoparticles have drawn attention towards their superior 
free radical scavenging abilities when compared to other agents such as Vitamin C, 
Vitamin E, PEG-SOD in clinical research12-14. 
 
Fig 1.1. The schematics of the representative carbon-based nanomaterials (Pic courtesy Creative Diagnostics) 
 3. Photothermal agents:   Currently, there is much interest in light absorbing 
materials such as metallic nanoparticles15, 16, semiconductor polymer nanoparticles17, 
18 and carbon-based nanostructures19, 20. The unique structure carbon composition, 
electrical and thermal characteristics offer a promising approach to cancer therapy. 
The idea is to place the multifunctional carbon nanomaterials at tumour sites and 
heating that site to impart photothermal effect via local hyperthermia21, 22.  
1.1.1. Mesoporous carbon nanoparticles as delivery 
systems 
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Among the various carbon-based nanocarrier systems, mesoporous carbon 
nanospheres have carved its niche as novel owing to its large surface area, open 
frameworks, mesoporosity, large internal volumes, chemical inertness and 
hydrophobicity. These numerous properties make them more noticeable and beneficial 
for high adsorption of hydrophobic drugs with the controlled release pattern and 
efficient cellular delivery 23, 24. They have been used for delivery of drugs, contrast 
agents and target molecules (genes, DNA, proteins) 25, 26. Owing to its hydrophobic 
properties, it has shown a better affinity towards hydrophobic anticancer drug 
molecules (ex, doxorubicin, cisplatin, paclitaxel, etc.) and has demonstrated enhanced 
antitumour efficiency 26. Thus, owing to the numerous advantages of mesoporous 
carbon-based nanocarrier systems, they have increasingly become desirable 
candidates for biomedical applications from the carbon family 23, 27-29. Mesoporous 
carbon nanoparticles are especially beneficial for delivery of therapeutic proteins9, 30. 
In chemotherapeutics, protein-based drugs are gaining popularity mostly because of 
its adequate potency lacking the random/ genetic side effects. Harnessing them for 
therapeutics holds more considerable promise for cancer treatment than conventional 
chemotherapy 31, 32. However, their fragile structures and extreme sensitivity to 
physicochemical changes in their immediate environment, such as hydrolysis, 
oxidation, proteolysis and denaturation necessitate having an escorting that can 
transport them successfully within the cytosol of the cell to elicit an effective 
response32.  It is anticipated that mesoporous carbon nanoparticles are porous and 
multifunctional; they could serve as a platform for next-generation nanocarrier system 
for diagnosis and therapy simultaneously 26, 31. Mesoporous carbon nanospheres are 
derived from the polymer sources under heating process in a nitrogen environment 28 
in which the treated carbonisation temperature determines the physicochemical, 
electrical and mechanical properties of final products 33, 23, 34, 35.  
1.1.2. Mesoporous Carbon nanoparticles as Antioxidant 
agents 
Recent preclinical studies have demonstrated that carbon nanomaterials exhibited 
superior antioxidant properties than those of dietary antioxidants, and it is an affinity 
towards cellular uptake 14 12.  Their antioxidant properties have shown impressive 
results in not only ROS generated diseases such as cancer etc.; but also showed 
promising performance in recovery and restoration in patients who suffered a traumatic 
brain injury.  However, among the various carbon particles utilised for biomedical 
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applications, mesoporous carbon nanomaterials hold a more significant promise as it 
has a carbonaceous composition with high porosity, biocompatibility, chemical 
inertness, cellular affinity, which are highly desirable traits for therapeutics strategies36-
38.  Moreover, owing to its physicochemical properties, it readily interacts with ROS 
species (hydroxyl radicals) in its natural form optimised by carbonisation temperature 
and displays ROS scavenging activity, which has never been reported in any other 
carbon nanoparticles. 
1.1.3. Mesoporous carbon nanoparticles as photothermal 
agents 
Colloidal mesoporous carbon nanospheres form stable suspensions in aqueous 
solutions and have exhibited high light absorption capabilities in UV-Vis-NIR region39, 
40.  Comparative studies with other photothermal agents such as gold nanorods, 
SWCNTs, graphene have shown mesoporous carbon nanospheres have 1.5-2 times 
higher than those of CNTs and graphene and are comparable to those of gold 
nanoparticles39. Additionally, due to high drug loading capabilities, they are also ideal 
candidates for the combination of tumour-suppression effect by using low drug dosage 
and laser power density.  Thus, the high drug loading capacity together with excellent 
photothermal effect makes them promising platforms for cancer theranostics. 
 Most of the carbon nanoparticles such as graphene, CNTs, carbon dots, nanohorns, 
etc., are functionalised to achieve colloidal stability, biocompatibility and enhance their 
biological performance. However, the performance of mesoporous carbon 
nanospheres can be optimized by optimising various aspects such as size, porosity, 
temperature28, 41. Although several studies show the impact of carbonisation 
temperature on the structural and morphological features34, 35 of the nanoparticles yet 
its impact on the biological behaviour has not been reported until now.  Through this 
PhD work, we have tried to address this exact query by studying the mesoporous 
carbon nanospheres and its behavioural and performance changes according to the 
change in the temperature of carbonisation. 
In the first part of the thesis, mesoporous carbon hollow spheres (MCHS) was 
synthesised using silica template method, carbonised at different temperatures 500°C- 
1100°C, followed by removal of the template. The porous MCHS were characterised 
and found MCHS-900 had the highest hydrophobicity and biocompatible among all 
samples, exhibiting superior RNase A (a model of therapeutic proteins) adsorption and 
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sustained release, beneficial for therapeutic protein delivery. RNase A delivered by 
MCHS-900 demonstrated significantly improved anti-cancer efficacy than free RNase 
A or delivered by MHCS-500 and MHCS 700. Furthermore, MCHS-900 also enhanced 
the cellular uptake of RNase A and successful endosomal escape, critical steps for 
therapeutic protein delivery. 
 In the second part, we investigated the optimised MCHS for highest antioxidant 
properties in the pristine state.  For this, MCHS was carbonised from 700 °C to 1300 
°C, their ROS scavenging activity was tested, and the optimised MCHS was selected 
depending on the highest ROS scavenging activity.  Furthermore, MCHS ROS 
scavenging activity was also compared to other carbon-based ROS scavenging 
agents in their pristine form. Extracellular ROS scavenging activity and intracellular 
ROS scavenging activity were analysed. EPR analysis of pristine MCHS carbonised 
at different temperatures revealed MCHS-900 carbonised at 900˚C has remarkable 
ROS scavenging profile in the aqueous environment.  Further comparative EPR 
analysis revealed that MCHS-900 is 3.2 times and 2.7 times more effective than CNT 
and RGO, respectively. Moreover, intracellularly, the same trend was observed where 
MCHS-900 emerged as the best antioxidant agent for ROS- mediated therapeutic 
approach.  
 Finally,  we explored the theranostic capabilities of MCHS. In this part, we again used 
MCHS carbonised at different temperatures, and we tested the up-conversion 
capabilities (conversion of absorbed light into heat) of mesoporous carbon hollow 
spheres in aqueous solutions. We also utilised MCHS as a nanocarrier system to 
deliver HSP 90 inhibitor intracellularly which works by inhibiting the heat shock 
chaperone protein in cancer cells making them ultra sensitive to thermal damage. 
Simultaneously, MCHS was irradiated with UV incident light, where the nanospheres 
absorbed the light and converted them into heat creating an environment of 
intracellular hyperthermia, thus inhibiting cancer cell proliferation.  
1.1. Research objective and scope 
The general aim of this project is to systematically investigate the optimisation of 
Mesoporous Carbon Hollow Spheres with carbonisation temperature and tuning its 
properties that determine its therapeutic behaviour in the biological environment. The 
specific aims include:   
1) To investigate the impact of carbonisation temperature on MCHS and their 
correlation with its intracellular protein delivery.  
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2) To investigate the optimised carbonisation temperature to elucidate the highest 
ROS scavenging activity to be utilised as a best antioxidant agent 
3) To investigate the theranostic abilities of temperature optimised MCHS delivering 
HSP90 inhibitor intracellularly to inhibit cancer cell by applying combination therapy 
(chemotherapeutics and photothermal effect) 
Our study will pave the way towards the development of next-generation, highly 
effective mesoporous carbon nanoparticles that can be applied as active biomaterial 
systems in cancer therapy via simple optimisation technique.  
1.2. Thesis Outline 
This thesis is written according to the guidelines of the University of Queensland. The 
chapters in this thesis are presented in the following sequence: 
 
Chapter Introduction 1  
This chapter includes a brief overview of the background of this research work 
including aims and significance of the work. 
Chapter 2 Literature Review 
This chapter presents a detailed review of the contributions made by mesoporous silica 
nanoparticles in drug delivery systems. Also, a detailed review of the contribution of 
particle shape and pore size of MSN in a biological application. 
 
Chapter 3 Methodology 
This chapter summarizes the strategies utilized in the whole PhD project, including 
synthesis strategy of mesoporous carbon hollow spheres and its carbonisation 
technique along with the techniques for material characterizations and biological 
evaluations. 
Chapter 4 Mesoporous Carbon Hollow Spheres: Carbonisation-
Temperature-Dependent Delivery of Therapeutic Proteins  
This chapter reports the influence of carbonization temperature of mesoporous carbon 
hollow spheres (MCHS) on their delivery performance of therapeutic protein in cancer 
cells.   
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Chapter 5 Antioxidant property of pristine mesoporous carbon 
hollow spheres (MCHS) for ROS mediated cancer therapeutic 
strategy 
This chapter reports the ability of MCHS to relieve intracellular oxidative stress, mainly 
prevalent in cancer cells, by its efficient free radical scavenging property. Here we 
measured the antioxidant property of MCHS carbonised at various temperatures to 
select the optimized MCHS for maximum scavenging activity.  We also tested the free 
radical scavenging activity of MCHS compared to other famous carbon scavengers to 
compare its effectiveness.   
Chapter 6 Photothermal ablation of cancer cells using temperature 
optimized mesoporous carbon hollow spheres 
This chapter reports the theranostics capabilities of MCHS by applying a combined 
therapy of chemotherapeutics and photothermal effect to inhibit cancer cells. We also 
tested the capabilities of MCHS to convert absorbed light into heat according to its the 
temperature of carbonisation. 
Chapter 7 Conclusion and Recommendations 
Conclusion and significant contributions of this work are highlighted, and 
recommendations for future work are presented. 
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   Chapter 2  
   Literature Review 
 The inception of the concept, "Nanotechnology”, was proposed by Richard Feynman 
in 1959 and since then, it has led to numerous developments in scientific and 
engineering disciplines. It has blessed researchers with the ability to investigate 
substances at a molecular level. Nanotechnology has raised the intrigue in generating 
innovative materials with outstanding properties revolutionising the field of chemistry, 
biology, material science, physics, engineering and biomedical sciences.42 
Nanotechnology is defined as a  realm of science that takes advantage of the 
transformation induced in materials at nanometers scale (nanomaterials) ranging from 
10-7 to 10-9 m in size, which would otherwise be absent in bulk form.  Nanomaterials 
at this small level start exhibiting novel physical, chemical and biological properties 
that can be utilised to create unique materials, devices and systems.43 Although, 
nanotechnology is a considerably new scientific field of interest; however, its impact 
has been utilised since ancient times. The most famous case of the use of 
nanotechnology in primaeval times was the “Lycurgus cup”, made by ancient Roman 
glassblowers using small gold colloidal particles. The influence of using those 
nanosized gold particles was observed when the cup changed colour from opaque 
green to translucent red after the light was shone through it44.  The astounding change 
in the optical property of the gold nanoparticles in its bulk form was discovered, but it 
took the scientific community several years before they realised the real potential of 
nanotechnology.   Nanotechnology has given rise to various ways of manipulation of 
matter at the nanometer scale that allows researchers to design and engineer novel 
and precise synthesis of nanomaterials for desired functions and applications. As a 
result, nanotechnology has become a hot commodity in today's scientific world, which 
has attracted interests from prominent industries, organisations and governments. 
"The Global Nanotechnology Market Analysis" conducted a compressive market 
assessment across the major geographies such as North America, Europe, Asia 
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Pacific Middle East, Latin America and Rest of the world and estimated that 
nanotechnology might reach a global revenue of USD 173.95 billion by 2025.  This 
goes to show how much of substantial investments are being made to build and 
expand this technology so that the possibility for developing future nanomaterials that 
are better, more efficient and effective in its respective applications becomes a reality. 
2.1. Nanocarrier technology in the biomedical application: 
Nanotechnology has given rise to a new age of hybrid science that exploits 
nanomaterials integrated into biological systems engineered to exhibit specific 
chemical and physical properties. The field of biomedical sciences has embraced 
nanotechnology with open arms after extensive investigations were carried out to find 
the potential of nanomaterials in medicine and biomedical applications such as 
imaging30, sensing and detection45, targeted drug46, 47 and gene delivery48, 49, medical 
implants50, nanodevices51 and disinfection52.    
  In recent years, plenty of development has been made in designing and engineering 
nanomaterials that are specially designed to possess unique structures and properties 
useful in escorting therapeutic biomolecules and drug molecules that are otherwise 
restricted by our bio-systems. Therapeutic bio-macromolecules such as nucleic acids, 
proteins, peptides, DNA analogues (e.g., hormones, monoclonal antibodies, 
vaccines), are mainly benefited as nanocarrier systems using both active and passive 
targeting strategies8-11.   
2.2. Protein therapeutics: 
Protein therapeutics pose tremendous opportunity as new age therapeutic method to 
alleviate some of the gravest of illnesses. Proteins are the building blocks that perform 
most complex and diverse roles in the human body to support and maintain balanced 
functions such as cellular signalling and gene expression that is hard for synthetically 
modified chemical moieties to replicate.   Most of the human diseases such as cancer, 
autoimmune diseases and infectious diseases are a result of mutations or 
abnormalities in the levels of essential proteins in our bodies 53. This has given 
researchers tremendous opportunities to explore its potential in biotherapeutics54, 
vaccines55, 56, tissue culture engineering57, embryonic stem cell regulation46,58-61. 
Moreover, proteins and peptides are being harnessed cell targeted oncotherapy and 
theragnosis as they are highly potent and precise therapeutic agents minus the 
random/ genetic side effects 31  and holds a  greater promise alternative medicine for 
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cancer treatment than conventional chemotherapy62.  Recently, FDA (Food and Drug 
Administration) approved the first protein therapy, manufactured by “Novartis”, which 
will be marketed as “Kymriah” also known as “CAR-T therapy” has shown remarkable 
results in bone marrow cancer that affects children and young adults. CAR-T therapy 
showed incredible potential when it was subjected to clinical trial. The clinical trial 
involved 63 children and young adults with a type of acute lymphoblastic leukaemia, 
83% of patients that received the CAR-T therapy had their cancers go into remission 
within 3 months. At 6 months, 89 % of patients who received the therapy were still 
living, and at 12 months, 79 % had survived.   
Although the potential of protein therapeutics is high, the presence of certain 
limitations confines the use of protein for therapeutic potentials such as poor cellular 
uptake, limited transportation into tissues and the blood-brain barrier, enzymatic 
hydrolysis, fragile tertiary structures that are easy to get deactivated or degraded in 
native forms 32.   That is why, nanocarrier systems are needed in the diagnosis and 
therapeutic practices, especially in cancer therapeutics to assist the target protein/drug 
molecule in overcoming cellular barriers and improving their intracellular 
concentration. The factors required for effective nanocarriers are summarized in 
Table1. 
Table 2.1 Rational design of nanocarriers for cancer therapy8, 53 
Advantages of nanocarriers over 
free drugs/biomolecules 
Requirements nanocarriers should 
meet 
Offers protection to the 
drug/biomolecule from premature 
degradation/ denaturation. 
Synthesized with a very biocompatible 
material, well characterized and easily 
optimized  
Enhances tissue absorption (like solid 
tumours) and overcomes multiple drug 
resistance 
Exhibit high cellular uptake efficiency in 
cancer cells 
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Improves intracellular penetration Be either soluble or colloidal under 
aqueous conditions for increased 
effectiveness 
Enhances bioavailability Have high drug/biomolecule loading 
capacity with controlled release pattern 
Controls the pharmacokinetic and 
pharmacodynamics interactions 
Have an extended circulating half-life, a 
low aggregation and a long shelf life 
Various nanocarrier systems have been synthesised such as polymer-based 
nanocarrier, lipid-based nanocarriers, micelles, quantum dots, nanofibers, magnetic 
nanoparticles, carbon-based nanoparticles, etc., to enhance the performance of 
therapeutic molecules while reducing the chances of potential side-effects.  Among 
the various nanocarriers, carbon nanocarriers have grabbed significant attention for its 
potential therapeutic drug delivery applications, especially in cancer therapeutics. 
2.3. Carbon nanoparticles as escorts for protein 
therapeutics: 
 Numerous studies have suggested carbon-based nanocarrier such as fullerenes, 
carbon nanotubes (SWCNTs, MWCNTs), carbon nano-horns, C-dots, nanodiamonds, 
porous carbon and graphene are incredibly beneficial in bio-medical applications for 
nanomedicine, drug delivery and bio-labelling, due to their distinct structures made up 
of uniquely hybridised carbons 1. Moreover,   carbon nanocarriers are innately 
hydrophobic in nature. This allows them to have a higher affinity towards highly 
hydrophobic anticancer drug molecules such as doxorubicin, cisplatin, paclitaxel, and 
in turn,  enhancing their bioavailability and effectiveness, which leads to enhanced 
antitumour efficiency. Presently most of the carbon nanomaterial allotropes used in 
biomedical applications possess desirable properties such as high cellular 
internalisation via various endocytotic mechanisms and fast endosomal release of 
protein conjugated carbon scaffolds into the cytoplasm that are essential steps to elicit 
is a fast and efficient response63. Using carbon nanomaterials as scaffolds enhance 
the utilisation potential of protein/ drug molecules which may solve the challenges in 
healthcare systems.  
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Carbon nanoparticles such as C-dots have reportedly suppressed cancer cells in vitro 
and are capable of inhibiting Hep G2 growth in liver cancer. Similar inhibition was seen 
in MCF-7 and MDA-MB-231 breast cancer cells where the cause was suggested to be 
due to the generation of large amounts of reactive oxygen species (ROS)64, 65. 
 CNTs is another popular choice for researchers as robust nanocarriers systems.  A 
leading effort in this field has been made by Dai group, which demonstrated multiple 
CNT based protein delivery platform for delivery in human cancer cell lines such as 
CHO and 3T366.  
Fig 2.1. Confocal microscopy images of HeLa cells after incubation in fluorescently labelled DNA-SWNT 
at (a) 37°C (b) 4°C, and (c) after pretreatment with NaN2. (d) flow cell cytometry data for HL60 cells that 
were incubated in fluorescently labelled pure DNA or protein solutions without nanotubes (labeled “DNA” 
and  “protein”, respectively), DNA_SWNT and SA-SWNT at 37°C, and protein-SWNT at 37°C in cells 
incubated at 4°C  or presented with sodium azide(image courtesy ref67). 
Nadine Wong Shi Kam et at. in 2006  investigated the delivery potential of proteins 
and DNA inside two different mammalian cells lines, adherent HeLa cells and non-
adherent HL60 cells.  
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Fig 2.2. The SDS-PAGE analysis of BSA-FITC without trypsin digestion (lane 1) and GO-PEG/BSA-
FITC and free BSA-FITC with trypsin cleavage for 1 h (lane 6 and 7), 3 h (lane 4 and 5), and 6 h (lane 
2 and 3), respectively (image courtesy ref61). 
In their study, they have shown that short SWNTs with right functionalization are 
capable of transportation of proteins and oligonucleotides into living cells via energy-
dependent endocytosis mechanism of cellular uptake.  Their cellular uptake and FACS 
data (Fig 1) showcased significantly elevated levels of fluorescing coming from cells 
introduced to carbon nanocarrier systems (SWNT) loaded with fluorescence-tagged 
proteins and oligoDNA proving the delivery efficiency of carbon nanocarrier systems.   
Another carbon allotrope, graphene oxide (GO), has also shown promising results in 
intracellular trafficking of the therapeutic protein. In 2012,  He Shen and co-workers 
reported PEG functionalized graphene oxide (GO-PEG) mediated protein delivery into 
cells. In their work, they delivered ribonuclease A (RNase A) which led to cell death 
and also transported protein kinase A (PKA) inducing cell growth and retaining their 
biological functions.  Firstly, using SDS-PAGE analysis of protein-FITC, they observed 
the changes in the protein before and after trypsin digestion at various time points and 
found that  GO-PEG/protein showed no discernable differences even after an hour of 
exposure where bare protein dissolved completely. The results (Fig 2); therefore, 
suggested protein loaded in  GO were reasonably protected from enzymatic 
degradation than naked protein. 
 Furthermore, cellular uptake studies done on HeLa cells treated with GO-
PEG/protein showed 42 % of cellular viability indicating high cytotoxicity caused by the 
intracellular delivery of therapeutic protein RNase A.  They also delivered functional 
protein PKA (Protein Kinase A) to elucidate the influence of functional proteins 
delivered by GO-PEG. They saw PKA-regulated pathways in MCF7 cells were retained 
causing enhanced cell growth in contrast to free PKA.  
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  Carbon nanocarriers such as graphene oxide, CNTs, nanohorns, carbon dots, 
fullerenes relies heavily on surface modifications and functionalisation to achieve 
higher biocompatibility, loading capacity, cellular interactions and sustained release68, 
69. However, mesoporous carbon nanocarriers are unique carbon nanocarriers that 
don’t rely on a surface modification to achieve those benefits. 
2.3.1. Mesoporous carbon nanospheres as nanocarrier 
systems: 
Among all the carbon family nanomaterials, mesoporous carbon nanospheres 
(MCNs) have drawn particular attention as the next generation of platforms for drug 
delivery and biomedical applications. When it comes to mesoporous nanomaterials, 
mesoporous silica nanomaterials (MSN) have gained the most attention owing to its 
large surface area, tunable pore size, high pore volume, large drug loading and storage 
capacity, biocompatibility, etc.   However, MCNs embody the benefits of both sp2 
carbon-based materials as well as MSN's. They  integrate a list of  various features 
such as: 
(i) large surface area and pore volume for favourable for high drug loading 
capacity  
(ii) adjustable pore structure enabling controlled the supramolecular release  
(iii) excellent biocompatibility and physicochemical stability  
(iv) easy surface modification and optimisation that enhances the therapeutic 
drug efficiency 
(v) supramolecular π-π stacking allowing the high drug loading  and sustained 
release of aromatic  and hydrophobic drugs  
(vi)  excellent heat conversion capacity  that provides possibilities of  
photothermal  therapy (PTT)   
(vii) unique optical properties and natural combination with photoluminescent 
giving us options of exploring theranostic diagnosis functions.   
Hence, it is anticipated that porous, multifunctional, multicomponent carbon 
nanoparticles could serve as a platform for next-generation nanocarrier system for 
diagnosis and therapy simultaneously26, 31. Thus, all of the benefits mentioned above 
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are making mesoporous carbon-based nanocarrier systems highly attractive 
candidates for biomedical applications23, 27-29. They have been used for delivery of 
drugs, contrast agents and target molecules (genes, DNA, proteins)25, 26. Owing to 
its hydrophobic properties, it has shown a better affinity towards hydrophobic 
anticancer drug molecules and has demonstrated enhanced antitumour efficiency 
26. However, mesoporous carbon nanocarriers are especially beneficial for active 
biomolecules like peptides, proteins, nucleic acids and therapeutic agents9, 30.  
Fig 2.3. Bright (a), fluorescence (b), and overlay CLSM images (c) of SKOV3 after incubation for 3 h 
with the rattle like dual‐pore mesoporous carbon/silica nanospheres MC@MS grafted with FITC 
group. d, e) Cytotoxicity of cisplatin and Ptxl drugs loaded into the MC@MS nanospheres, cisplatin 
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alone loaded into MC@MS nanospheres, and dual‐pore mesoporous MC@MS nanospheres at the 
same dose in different human ovarian cancer cells (d) normal ovarian cancer cells SKOV3, and (e) 
drug‐resistant A2780 (CP70) cells(image courtesy ref70).  
In recent years, Yin Fang and their co-workers synthesized dual–pore mesoporous 
carbon@silica composite nanospheres (MC@MS) for multidrug delivery, Fig 3. The 
hierarchical mesostructure and amphiphilicity of the hydrophobic carbon cores and 
hydrophilic silica shells led to distinct benefits in multi-drug combination therapy with 
anticancer drugs (Cisplatin and Paclitaxel) for the treatment of ovarian cancer 
including drug-resistant strains. 
When they conducted a visual test using the confocal microscope of the cellular 
uptake of MC@MS in  SKOV3 cells, they observed remarkable intracellular 
luminescence coming from the cytoplasm of the cells indicative of high cellular 
trafficking capability. Moreover, the cytotoxicity tests indicated  MC@MS loaded with 
both cisplatin and paclitaxel (denoted as MC@MS‐Pt‐Ptxl), killed more than 50% of 
the cancer cells, indicating efficient therapeutic effect of the nanocarrier loading with 
chemical drugs for the normal human ovarian cancer cells when compared to MC@MS 
loaded with only cisplatin (denoted as MC@MS‐Pt).  In cisplatin‐resistant A2780 
(CP70) cells were cultured with a specific amount of MC@MS‐Pt for 24 h, over 80 % 
of the cells were found to be alive.  However, when the same cells were cultured with 
the same amount of MC@MS‐Pt‐Ptxl for 24 h, over 50 % of cisplatin‐resistant cells are 
killed by the multidrug system.  Their work showcased the performance of anticancer 
drug were enhanced significantly by the use of mesoporous carbon nanocarrier 
system and its tremendous potential for therapeutic cancer utilisation. 
Fig 2.4 Schematic representation of protein loaded mesoporous carbon nanospheres for an enhanced 
immune response for vaccine delivery (image courtesy ref71).   
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 Not only mesoporous carbon enhance anticancer drug activity, but they are also 
excellent carrier systems for biomolecules for medical application. Recently, Hongwei 
Zhang and co-workers from our research group demonstrated the high loading 
capacity of biomolecules such as “lysozymes” and “oligoDNA” mesoporous hollow 
carbon spheres (MHCS) for biomedical applications. Through his work, he 
demonstrated high loading of the biomolecules with rapid adsorption kinetics. The 
oligoDNA were tagged with cyanine dye (Cy3), were loaded in MHCS and human 
colon cancer cells (HCT-116) were treated with them. Confocal images of the cells 
showed strong signals from cells indicating high delivery of cargo biomolecule 
indicating the efficiency of mesoporous carbon nanospheres. Similarly, when Manasi 
Jambhrunkar, also from our research group tested the efficacy of mesoporous carbon 
nanospheres as an adjuvant system, she observed promising biological effects, Fig 4.  
In her work, she highlighted the high loading capacity off vaccine proteins in the 
nanostructures, and when it was delivered as a vaccine on naïve 8-week-old C57BL/6J 
female mice, it showed amplified immune response to the delivered antigen.  Although 
pristine mesoporous carbon nanospheres were highly biocompatible, exhibited little to 
no immunological response on its own, however, when antigen protein (OVA) were 
loaded in the nanoparticles. Moreover, in-vivo immunisation studies in mice 
demonstrated that OVA-loaded mesoporous carbon nanospheres induced a 3-fold 
higher IgG response compared to a traditional adjuvant QuilA used in veterinary 
vaccine research.   
Thus, mesoporous carbon nanospheres not only showcased their potential as 
efficient intracellular nanocarrier systems but also has the potential to be utilized in 
cancer therapeutics for efficient and effective anti-cancer effects than conventional 
chemotherapy. 
 The primary reason mesoporous carbon nanocarrier’s effectiveness lies in their 
fabrication process. Unlike other nanocarriers, mesoporous carbon nanocarriers are 
very easy to synthesize using templating methods and are engineered to possess 
desirable qualities and morphologies suited for their desirable role. 
 2.3.2. Synthesis of mesoporous carbon nanospheres 
 Nanostructured porous carbon nanomaterials have been applied to various 
applications such as gas storage, capacitors, adsorbents, electrode  materials, gas 
storage and catalytic supports owing to its porous structures, high surface area and 
high adsorption capacity.   With the increasing amount of investigation being carried 
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out in mesoporous carbon structures, scientists have discovered their incredible 
potential to be excellent nanocarrier systems with high cellular internalization capacity.  
Porous carbon materials can be classified into three different categories namely, 
microporous (pore size<2 nm), mesoporous (2 nm<pore size<50 nm) and 
macroporous (pore size>50 nm)72. The primary way ordered mesoporous carbon 
materials are synthesized by carbonizing carbon precursors such as polymers, resins, 
etc. fused with a sacrificial template that makes the well-controlled porous frames. 
Current syntheses strategies can be categorized as either hard-template or soft 
template methods. The hard templating method involves the use of organic and 
inorganic templates that mainly serve as moulds for the replication of mesoporous 
carbon materials, and no significant interaction happens between the template and the 
precursors. On the other hand, the soft templating method involves the self-assembly 
of organic molecules. The corresponding pore structures are determined by the mixing, 
synthetic conditions, solvent and temperatures. Unlike hard template synthesis soft 
template involves the chemical interactions of the templates and carbon precursors.   
The first reported synthesis of carbon nanomaterials was by Knox and co-workers who 
fabricated nanomaterials using a spherical sol-gel as a template73.  Their approach 
included the following steps (a) preparation of silica template with controlled pore 
structure (b) impregnation or infiltration of the template with monomer or polymer 
precursors (c) crosslinking of the organic precursors followed by carbonization and 
finally (d) removal of the silica template.   Knox et al. used the phenol-hexamine mixture 
as the carbon precursor. After the polymerization, the phenolic resin was carbonized 
inside the pores of the spherical silica gel to transform into carbon structures. The 
dissolution of silica template resulted in rigid, spherical mesoporous carbon. They even 
commercialized the carbon material as “Hypercarb” that were used in making unique 
retention characteristics in liquid chromatography.  The synthesis approach 
established by the Knox group is being followed to this day as the most reliable and 
standard way of synthesizing mesoporous carbon nanostructures using the hard 
templating method.  
 Recently, Hongwei Zhang and co-workers from our research group successfully 
synthesized mesoporous carbon nanospheres using a hard silica templating method.   
His work demonstrated a simple one-pot synthesis process based on an in situ 
generated primary silica particles as templates, Fig 5. The highlight of the work was 
the ability to control the pore size which was adjustable from micropores to 13.9 nm. 
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Tetrapropyl orthosilicate (TPOS) and tetraethyl orthosilicate (TEOS) was used as a 
silica source, and resorcinol-formaldehyde (RF) was used as a carbon precursor 
source. First, they let the silica source to hydrolyse in order to form primary silica 
particles, after which RF oligomers polymerized and co-condensed onto the SiO2 core 
particles forming a SiO2@SiO2/RF core-shell structure. Then the polymer-silica matrix 
was carbonized followed by the removal of SiO2.  The ratio of TPOS and TEOS were 
adjusted and depended on the ratios the pore sized were determined.   He also 
reported using the hard templating method multilayered structures (bi- and triple-
layered), and controllable morphologies (invaginated, endo-invaginated, and intact 
spheres) could also be synthesized with high mesoporous volume28, 74, 75. 
  
Fig 2.5. Graphical representation of mesoporous carbon hollow spheres with polymer carbon precursors 
embedded into silica template on the left while the right shows the finished mesoporous carbon hollow 
spheres after carbonization and removal of silica template. 
 Taking into account the ease of synthesis and the control over nanofabrication of the 
nanomaterials we prepared our carbon nanocarrier systems using the hard silica 
templating, one-pot synthesis method. As mentioned earlier mesoporous carbon 
nanocarriers give the engineering freedom to manipulate its features in order to 
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accommodate its role. Features such as porosity36, 39, shape36 and size76 have been 
altered by controlling the synthesis process to acquire desired benefits. However, no 
reports have been published so far (to best of our knowledge) regarding the influence 
of carbonisation temperature on mesoporous carbon nanocarriers in biomedical 
application. 
2.4. Parameters for optimisation of the physicochemical 
properties of carbon particles 
As the use of nanocarrier systems increased in the biomedical applications, so did 
the assessments regarding the factors that influence their interactions with the 
biological environment. Research intended to associate the properties of 
nanomaterials such as size, shape, chemical functionality, surface charge, and 
composition with bio-molecular signalling, biological kinetics, transportation, and 
toxicity in both cell culture and animal experiments is vital 77. These studies help set 
the foundations for engineering the next generation of nanoscale vectors and 
devices77-80. As the synthesis process of nanomaterials is essential to discover new 
therapeutic escorts, the tuning of the properties of the nanocarrier is just as vital. 
Continuous efforts are being made to improve the therapeutic delivery systems to 
maximise the therapeutic effect of the drug while diminishing its undesirable side 
effects. As far as carbon-based nanocarrier systems are concerned, they are no 
exception to the factors mentioned above and they do influence them to a certain 
extent. The application performance of mesoporous carbon nanospheres is strongly 
influenced by numerous factors such as surface modification, particle, pore size, 
reaction time and reaction temperature36, 75, 81, 82. Optimization of such factors helps it 
to attain desirable properties such as higher stability, loading capacity, better 
bioavailability, better encapsulation, controlled drug release, the possibility of 
incorporation of both hydrophilic and hydrophobic substances, the feasibility of 
variable routes of administration, which are vital features for carbon nanocarrier 
systems to consider as efficient drug delivery systems. 
2.4.1. Carbonization temperature influence on mesoporous 
carbon nanospheres. 
“Carbonisation temperature” is the key factor that dictates the physical, chemical, the 
electrical and mechanical behaviour of carbon-based nanomaterials 33. Carbonization 
in itself is the most vital step in the synthesis of mesoporous carbon nanospheres 
23 
 
where the carbon precursors (such as polymers, resins, etc.) are converted into pure 
carbon structures at controlled elevated temperature conditions. Carbonisation 
increases the percentage of carbon content as well as introduces pores. As a result, 
the physicochemical properties the carbon nanomaterials possess such as adsorption 
capacity, solubility, hydrophobicity, crystallinity, etc., are also essentially brought about 
by influenced23, 34, 35. Studies were done on the effects of temperature during pyrolysis 
on carbon-based nanomaterials which showed, temperature change directly 
influences its performances in various applications such as fuel cells 83, catalysis84, 
and gas separation85, but this investigation has not been extended to the biomedical 
applications.  While other carbon nanomaterials require functionalization and 
modifications to improve its colloidal stability in aqueous solutions; mesoporous carbon 
nanospheres show excellent colloidal stability modified with thermal changes during 
the carbonization process. Mesoporous carbon hollow spheres (MCHS) have shown 
excellent delivery performance in previous reports but at a fixed carbonisation 
temperature28. 
 In 2001, Tse-Hao Ko et al. investigated the changes in the structure and crystallinity 
of the phenol-formaldehyde resin  system that were carbonized and graphitized  at 
from 300°C to 2400°C35.  In their work, they traced the transformation of polymer resin 
into carbon framework using Raman spectra and X-Ray diffraction, Fig 6.  They found 
that transformation of the phenolic resin into carbon starts at 500°C, no carbon 
structures are formed at a temperature below 400°C, and  the original resin structure 
disappeared entirely above 600°C  .  As the carbonization temperature rose  from 
600°C   to 1000°C,  the carbon crystal size  of the polymer resin increased. Moreover, 
above 1000°C  the carbon  started to graphitize  as the stack size of carbon  increase  
and the frequency of the G band and D band starts   getting closer to 1582 cm-1 and 
1357 cm-1 respectively.   
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Fig 2.6. (A) The wide- angle X-ray diffraction pattern of cured resins during pyrolysis (B) The graph 
shows the variation of the weight loss and shrinkage of resulting carbonised resins as a function of the 
pyrolysis temperature (image courtesy reference86) 
The same group also  observed the changes in the microstructure and 
physicochemical properties in the phenol-formaldehyde resin  after carbonization at 
different temperatures.  Their results showed carbonization temperature brings 
significant changes such as  weight loss, shrinkage, pore formation, volume 
expansion, etc86.  
 The studies demonstrated the importance of carbonization temperature, and it 
impacts on the structure and behaviour  of  carbon nanomaterials.  Moreover, due to 
the changes brought about by the carbonization  temperature their  features can be  
tuned and optimized by  tuning the carbonization temperature.  
2.5. Carbon nanomaterials as ROS scavengers 
  Not only does carbon nanocarrier systems are excellent escorts for therapeutic 
drugs, but they are very efficient  free radical ROS scavengers as well often attributed 
to their long conjugated C=C carbon chains87.  Over the years, a plethora of research 
has suggested a direct correlation of the elevated level of ROS, i.e. an extended state 
A B 
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of oxidative stress, to major chronic diseases including cancer, rheumatoid arthritis 
(RA), neurogenerative diseases, acute ischemic injury, etc14. The current clinical 
recommendations for oxidative damage is to use classical antioxidants that have 
shown little to no benefit in the treatments.    Some of the popular antioxidants have 
been listed in Table 2. The factors that might be a reason for hindrance for the  
efficiency of the antioxidants are as following (i) they require additional enzymes to 
assist them in detoxifying the radical molecule (ii) limited number of radicals removed 
per antioxidant moiety (iii) production of other radicals  due to  antioxidant's mechanism 
intended to neutralise the free radicals12, 88. 
Table 2.2.  Various antioxidants with their mechanism of action88 
Antioxidants Target 
ROS 
Number of 
ROS 
removed 
per 
molecule 
ROS  
generated 
Detoxifying 
enzyme 
SOD O2•―  2 H2O2 None 
Catalase H2O2 2 None None 
Glutathione 
peroxidase 
H2O2 1 None None 
Glutathione H2O2 1 None Glutathione 
reductase 
Vitamin E O2•―, R• 1 E Vitamin C 
Vitamin C E• , R• 1 C Dehydroascorbate 
reductase 
Albumin HO•  Unknown None 
(presumably by 
disulphide 
formation) 
None 
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That is why particle-based systems are being considered as an emerging class of 
active antioxidants due to the possibility of complete quenching of radicles without the 
need for assistance from detoxifying molecules. Carbon materials such as SWCNT, 
MWCNT, graphene, fullerene or their other derivatives are being aggressively 
investigated as antioxidants owing to their potential to scavenge free radicals 
effectively. 
In 2012, Brittany R. Bitner and co-workers tested PEG- functionalised hydrophilic 
carbon clusters (PEG-HCCs) as antioxidants to reduce the cerebral blood flow (CBF) 
in rat model inflicted with mild traumatic brain injury (TBI)/ hypotension/resuscitation.  
As elevated levels of ROS such as superoxide (SO) have been detected in the 
vasculature and spikes of ROS, have been found following a trauma; the damaging 
spikes in the level of ROS continue upon blood reinfusion during resuscitation and 
blood reinfusion which further ensues oxidative damage.  The authors theorised, a 
potent, non-toxic clinical agent should be administered following the release of ROS 
that has ROS annihilation capabilities at a clinically realistic time point. So, in their 
work, they administered functionalized carbon clusters as therapeutic ROS scavenger. 
The results indicated that non-toxic PEG-HCCs normalised the oxidative radical profile 
and restored cerebral perfusion.  Since cerebral perfusion following even a mild TBI is 
a vital cause of poor outcome, the ability of PEG-HCCs to restore ROS levels were 
supportive of a treatment that can potentially  improve the neurological prognosis for 
traumatised patients. 
PBN O2•―,  HO• 1 Nitroxide free 
radical 
None 
Tempol O2•―,  
ONOO― 
1 H2O2 , NO• None 
Fullerene 
derivative 
(C60) 
O2•―,  HO•  Unknown None None 
PEG- HCC O2•―,  HO• Estimated 
106 
H2O2 None 
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 Due to the high ROS scavenging capabilities of carbon nanomaterials, it has also 
been investigated for its ROS mediated immunomodulatory behaviour.   Recently, in 
2016, Redwan Huq and co-workers discovered that carbon nanomaterials as superior 
antioxidant agents could be utilised for cell- targeted immunotherapy.  They reported 
functionalised carbon clusters which are known ROS scavengers have a preferential 
internalisation by T- lymphocytes over other splenic immune cells. They exploited this 
selectivity to inhibit T cell activation without affecting significant functions of 
macrophages, APC cells that are crucial for T-cell mediated inflammation in delayed 
hypersensitivity in experimental autoimmune encephalomyelitis (EAE, a model of 
multiple sclerosis).  They assessed the consequences of PEG-HCC internalisation and 
found a significant reduction in intracellular ROS levels after administration of carbon 
nanoparticles. Consequently, ~30 % reduction in the intracellular pro-inflammatory 
cytokines such as TH1 cytokines, interleukin (IL)-2 and interferon (IFN)-γ were 
observed which are critical cytokines in autoimmune diseases such as multiple 
sclerosis. Moreover, after the histological analysis was conducted of the spinal cord 
grey matter collected from clinical models of rats with acute EAE, they found a 
decrease in inflammatory foci after 12-days post- immunisation.  This suggested PEG-
HCC reduced immune cell infiltration into the central nervous making it a potential and 
highly active antioxidant agent for immunomodulation for autoimmune diseases. 
 Fullerenes and its functionalized derivatives are one of the most popular 
nanomaterials that have exhibited high anti-oxidative capability in reducing ROS-
induced injuries in biological systems. Empty fullerenes with big conjugated π-system 
can efficiently capture electrons and can be utilised as ROS scavengers. Although 
their low solubility restricts pure fullerenes in the hydrophilic environment; 
functionalized and modified fullerene have shown remarkable success as antioxidant 
carbon nanomaterials to alleviate detrimental effects of elevated ROS content.  They 
have been studied for various ROS-induced injuries including ROS mediated cancer 
prevention strategies. In 2016, Jie Li and co-workers designed water-soluble 
metallofullerene Gd@C82 (Ethylenediamine)8 nanoparticles that exhibited remarkable 
cytoprotective effect against peroxide-induced injuries to human epidermal 
keratinocytes-adult (HEK-a) cells at a minuscule concentration of 2.5 µM.   Using EPR 
analysis,Fig 7, they found that Gd@C82 (EDA)8 NPS had ~81% reduction in hydroxyl 
radical (OH•, the most common radical found in the human body).  The cellular study 
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also indicated high intracellular scavenging activity by increasing the cell viability by 
approximately 20%, protecting the cells from ROS included injuries.   
  
Fig 2.7. Diagrammatic representation of intracellular ROS scavenging ability of carbon nanoparticles89. 
Not only has that, but carbon nanoparticles also showed noteworthy resulted in the 
management of rheumatoid arthritis (RA). In 2009, Kazuo Yudoh and co-workers 
demonstrated that water-soluble fullerene carbon nanoparticles are great protective 
agents against synovitis in arthritis both in-vivo and in-vitro. They used adjuvant-
induced arthritic rats were used as a model of arthritis. It was found that water-soluble 
C60 significantly suppressed the TNF-α induced production of proinflammatory 
cytokines in synovial fibroblasts, synovial infiltrating lymphocytes and macrophages in-
vitro.   Moreover, histological analysis of the ankle joint revealed C60 significantly 
reduced synovitis and alleviated bone resorption and destruction of in the joints 
compared to animals who were categorized as control groups.  
 All the above stated fascinating research points towards the fact that carbon 
nanomaterials have an excellent ROS scavenging ability that can be utilized as a 
potential therapeutic agent for various ROS mediated diseases.  
 
 
Carbon Nanoparticles 
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2.6. Photothermal therapy (PTT) using carbon 
nanomaterials as photothermal agents 
Photothermal therapy (PTT) or photothermal cancer therapy has garnered significant 
attention as an innovative cancer treatment strategy over traditional cancer therapies 
such as chemotherapy, radiation therapy and surgery. PTT strategy involves using 
specific light sources to induce heat, creating an environment of hyperthermia to kill 
cancer cells90.  Interest in PTT started in the nineteenth century; however, it started to 
gain momentum in the 1980s owing to rapid development in optical and nanomaterial 
technology91. PTT is an effective cancer therapy that creates a state of hyperthermia 
after administration and light treatment, elevating the temperature to 40° C- 43°C92. 
Temperatures at this range have clinical significance as several cellular reactions such 
as protein denaturation, aggregation and cell inactivation occurs that disrupts or 
damages the cellular homeostasis in cancer cells causing lower survival rate, cell 
necrosis or cell apoptosis91, 92. Currently, PTT is being developed and encouraged for 
innovative cancer therapeutic strategy. This strategy is useful and attractive as it 
blends the unique advantages of being highly selective/ specific with minimum 
invasiveness. If the proper photoabsorbers / photothermal agents are employed in 
PTT, it can directly eradicate the cancer cells in a primary tumour or local metastasis 
to combat the initial stage of cancer metastasis and can also be employed in 
combination with current therapeutic modalities. The strategy has been graphically 
represented in Fig 2.8.  This helps achieve the precise heating of the cancerous region.  
Rapid developments in nanotechnology have allowed the investigation of a variety of 
specialised nanomaterials such as conducting metallic and semiconductor materials93, 
organic polymers94, quantum dots95, carbon nanomaterials91   for in vitro as well as in 
vivo PTT. Carbon nanomaterials have proven to be excellent choices for photothermal 
agents as they have desirable properties such as i)relatively higher absorbance of light 
wavelength (nm) ii)good biocompatibility iii)good dispersion in biofluids such as 
blood91. Taking advantage of the ability of carbon nanomaterials to harvest light, 
convert it into heat and biocompatibility, they are being investigated for potential 
candidates for "photothermal therapy" (PTT) as "photothermal agents" or “theranostic 
agents”. Carbon-based nanomaterials such as CNT, carbon nanohorns and graphene 
have been extensively studied as potential PTT agents96-98.  
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Fig 2.8. Schematic representation of PTT therapy using carbon nanomaterials as photothermal agents 
 
 Most of the investigation has been done using carbon nanotubes for potential PTT 
application for cancer therapeutics.  In 2009, Hye Kyung Moon et al. used single 
carbon nanotube as a photothermal therapeutic agent to treat a localised tumour in 
vivo, represented as a scheme in Fig 2.996.  In their work, they induced human 
epidermoid mouth carcinoma KB tumour cells via xenograft on mice’s backs.  
Approximately 120mg/L, 100µL of PEG-SWNTs were injected into the tumour region, 
and the near-infrared laser was irradiated for 3 min. Post-treatment they observed that 
when PEG-SWNTs were combined with laser irradiation, by the 14th day of treatment, 
there was a noticeable reduction in the tumour volume whereas, by the end of 20 days 
of treatment, the tumours were destroyed entirely.  They also observed a residual black 
mark on the skin as a burn mark which was direct evidence of excessive local heating 
caused by the photothermal agents by the laser irradiation.  
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Fig 2.9. Schematic diagram representation of carbon nanotubes used in cancer cell ablation in PTT 
(image courtesy ref96)  
  Another exciting work on carbon nanomaterials came from Daiqin Chen and co-
workers in 2014 who demonstrated photoacoustic imaging-guided NIR photothermal 
therapy using carbon nanohorns as theranostic agents99.  In their work, they used 
single-walled carbon nanohorns (SWNHs) as photothermal/theranostic agent and 
functionalised it C18 PMH-PEG to optimise their EPR effect, enhance their 
accumulation in the tumour site and diminish toxicity in pristine form.  Firstly they 
conducted cell growth inhibition assay where they tested the ability of nanomaterial to 
inhibit the growth of 4T1 cells either with or without laser irradiation. They observed 
after incubation of 4T1 cells, only after irradiation of laser at a specific power density 
of 0.6 Wcm-2 was there significant inhibition of the tumour cells. Furthermore, they took 
a 4T1 tumour bearing female Balb/c mice and intravenously injected with SWNHs/C18 
PMH-PEG (2mg mL-1, 200µL) and tested the photoacoustic image of a tumour and 
tumour ablation capabilities of the nanomaterials after laser irradiation. After 
calculating the mean signal intensity and maximum mean signal intensity of the region 
of interest, they found excellent photoacoustic effect which kept intensifying after ~24 
hours post-injection.  They also tested the photothermal ablation of tumour post 24 
hours of i.v injection and exposure of the tumour region to a laser with a power density 
of 0.4 Wcm-2. They observed that the temperature reached almost ~55°C after 
irradiation, the tumour size shrunk significantly, and the mice made a full recovery after 
16 days of treatment.  Similar to Hye Kyung Moon’s (mentioned above), the tumour 
32 
 
site was left with black scar (crust) indicating the thermal ablation and regrowth of body 
hair on the site without recurrence of a tumour.   
 Among the carbon nanomaterials family, carbon nanotubes are the most popular 
choice when it comes to photothermal therapy. However, its sister “graphene”, has not 
been far behind. In work done by Kai Yang and co-workers, they tested the 
photothermal ablation efficiency of PEG-functionalized graphene nanomaterials in-
vivo.  When they used a NIR laser with a power density of 2 Wcm-1 in an aqueous 
solution, they observed rapid rise in the temperature within a very short period.  They 
also tested the PEG functionalized nanographene sheets on 4T1 tumour model on 
Balb/c mice. Then they injected 200µL of carbon nanomaterial in the tumour region 
and irradiated the site for 5 min after 24-hours post-injection.  They found the surface 
temperature of ~50°C in contrast to uninjected mice which reached to just ~2°C.  The 
survival curves of the mice showed all the mice treated with photothermal treatment 
survived over 40 days without any single death.  
 Studies on the potential advantages of using carbon nanomaterials as photothermal 
agents are pretty promising, with significant shrinkage of a tumour and high mice 
mortality rate, carbon nanomaterials have geared themselves for possible future 
medical cancer diagnosis.  However, when it comes to photothermal agents from 
carbon family, mesoporous carbon nanospheres might have the upper hand owing to 
its porous structure in combination with the photothermal property of sp2 carbon 
nanomaterials.  Mesoporous carbon nanospheres are hybrid nanocomposites that can 
be utilized for drug storage in the nanopores and can convert heat from light irradiation, 
making it a better performer for photothermal cancer therapy.  This advantage of 
mesoporous carbon nanospheres was investigated by Guiju Xu and co-workers in 
2014. Their group used functionalized mesoporous carbon nanospheres for a 
combination of cancer therapy that includes chemotherapy and photothermal therapy 
acting as synergists with a common goal of cancer cell destruction. In their work, they 
modified the mesoporous carbon nanospheres with folic acid for targeted 
chemotherapy, loaded doxorubicin hydrochloride (DOX) taking advantage of the high 
loading capacity and treated Hela cells following with photothermal therapy. When they 
subjected the nanoparticles to the Hela cells, they found that cytotoxicity of 25µg mL-1 
carrying an equivalent of 13 µg mL-1   of DOX killed 64 % of the cells, whereas when 
the dose was combined with photothermal therapy, the cellular inhibition increased to 
74%. Thus, mesoporous carbon nanospheres demonstrated the ability to significantly 
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enhance their cancer therapeutic efficiency with its photothermal efficiency being 
applied in combination with chemotherapy.  
 2.7. Conclusion: 
  Cancer therapeutic practices have gotten a whole new spin after the introduction of 
nanocarrier systems. Nanocarrier systems allow us to exploit relatively potent and 
safer therapeutic proteins or biomolecules to treat cancer / tumour cells without 
sacrificing its effectiveness or damaging its fragile structure.   This has the potential to 
give rise to the next generation of chemotherapeutic treatment that will be safer and 
efficient method than conventional chemotherapy.  Among the various nanocarrier 
systems that have been developed over the years, carbon nanocarrier systems such 
as CNTs, graphene, fullerenes, nanohorns, C-dots, mesoporous carbon nanospheres, 
etc., have made their own mark  while proving their efficacy. Their uniquely hybridised 
carbon structures, inherent hydrophobicity, high surface area, high drug loading 
capacity, controlled release pattern, biocompatibility and high cellular uptake puts 
them into an enormous advantage over other groups of nanocarrier systems.  Among 
the various carbon nanocarrier systems been investigated so far, mesoporous carbon 
nanospheres possess numerous benefits that make us consider them for numerous 
biomedical applications.  Mesoporous carbon nanospheres have all the benefits of sp2 
hybridized carbon materials along with an open porous framework with the large 
surface area . Thus, it  achieves  high loading capacity, high cellular delivery and 
controlled release of the load  with  high cellular interaction. They also enjoy high 
colloidal stability  which can be achieved by conditional optimization.  Mesoporous 
nanocarbon nanomaterials  fabricated using nano casting method employing a hard 
porous silica template gives better control of the structure and porosity of the 
nanomaterials. First, they synthesize the porous silica template followed by infiltration 
of the template with carbon precursors. Then the polymer-silica matrix is carbonised, 
and at the final stage, the silica template is removed leaving us with the porous carbon 
framework. “Carbonization” is a vital step in the fabrication process as it dictates the 
carbon content, formation of C=C chains, morphology, crystallinity, etc., which 
determines the physicochemical properties of the mesoporous carbon nanospheres. 
In this PhD thesis, we have carried systematic study of the structural, chemical and 
behavioural changes occurring in mesoporous carbon spheres upon carbonization at 
various temperatures.  In chapter 4 we synthesised mesoporous carbon hollow 
spheres (MCHS) using the one-pot synthesis method using porous silica particles. We 
primarily focused on the carbonization of polymer and silica matrix into carbonaceous 
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frameworks and their physicochemical changes at various temperatures.  We also 
investigated the trend of the cellular interaction of the mesoporous carbon 
nanospheres carbonised at different temperatures in order to  figure out the “optimised 
temperature” that  can elicit the  highest intracellular therapeutic delivery performance. 
  In chapter 5 we discussed the potential application of MCHS as free radical 
scavengers. As long conjugated carbon chains are attributed to the free radical 
scavenging that can also be beneficial for various ROS related ailments. In this PhD 
project, we dived into the potential of MCHS as efficient ROS scavenging 
nanoparticles.  We also investigated whether the carbonization temperature influences 
the ROS scavenging ability of the nanoparticles or not. Furthermore, we tested MCHS 
after intracellular and its ability to diminish oxidative stress which is a ubiquitous sight 
in a tumour or cancer cellular environment.  This included MCHS carbonised at an 
optimized temperature which shows the highest scavenging efficiency being compared 
with conventional and popular ROS scavengers as well as with other carbon 
nanocarrier systems.  
 The versatility of MCHS was extended in chapter 6 where we investigated the 
photothermal property of MCHS.  Carbon nanocarrier systems are also great 
facilitators of photothermal conversion of pointed incident light into heat. This heat can 
be harvested to kill cancer cells and act as a synergist support nanocarriers that can 
carry therapeutic drug molecules and release them in the cytosol of the cancer cell 
while upconverting projected light into heat resulting in higher cancer cell cytotoxicity.  
We tested the photothermal of MCHS prepared at various carbonization temperatures 
under aqueous conditions. We also tested cancer cellular toxicity of optimised MCHS 
carrying HSP90 protein inhibitor (a drug molecule that inhibits the resistance of cancer 
cells to photothermal damage) and its photothermal ablation in MCF7 breast cancer 
cells. 
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   Chapter 3       
Methodology 
This chapter summarizes the strategies utilized in the whole PhD project, including a 
synthetic method for the preparation of MCHS-T. It also discusses the methods and 
instruments used for the characterisations, detection methods and evaluations. 
3.1. Material Synthesis 
 Mesoporous Carbon Hollow Spheres (MCHS) were synthesised using the hard 
templating method.  MCHS was obtained after carbonising silica/polymer composite, 
where silica played the role of the hard template whereas the remainder carbon shell 
was a result of the pyrolysed polymer matrix. Tetrapropyl orthosilicate, TPOS; was the 
choice for silica precursor whereas Resorcinol Formaldehyde, RF; was used as the 
polymer source considering their suitable polymerisation kinetics for forming a sizeable 
mesoporous volume. At first, TPOS was added to the solvent system to hydrolyse, 
then self- assemble and homogenously nucleate to form monodisperse Stöber 
spheres, which acted as silica core. Later, the added RF precursors start to polymerise 
and initiate the heterogeneous nucleation process by growing on the surface of the 
silica core. At the reaction time, reaches the ~ 2-hour mark, the RF oligomers starts to 
co-condense along with primary silica particles and interact through weak hydrogen 
bonding forming a SiO2@SiO2/RF core-shell structure. The SiO2/RF shell continuously 
increases in thickness as the reaction continues and the size of the mesopores in the 
final structure is determined by the size of the silica aggregates co-condensing along 
with the polymer oligomers.  Since TPOS has a high concentration of slow silica 
primary particles, it favoured the formation of large aggregated silica particles co-
deposited with the RF oligomers causing large mesopores to form. After the final 
SiO@SiO2/RF matrix is formed, they were carbonised where the RF polymer was 
converted into carbon crystals. The carbonisation temperature plays a vital role in 
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determining the carbon crystalline symmetry, structure, chemical bonding, carbon 
content (percentage), etc., which in turn influenced its functionality and applications.  
 
 
 
Scheme 3.1. A schematic representation of the one-pot synthesis of MCHS-T  
 
3.2. Material characterisation 
3.3.1 Transmission electron microscopy 
Transmission Electron Microscope (TEM) is a high-resolution imaging tech nique 
which utilises energetic electrons to provide morphologic, compositional and 
crystallographic information even on small volumes of samples. TEM is a powerful 
microscope with a maximum potential magnification of 1nm producing precise 2D 
images of the desired samples. In our work, TEM was crucial to carry structural 
characterisation of the local structure of samples [1, 2]. In this PhD project, all the TEM 
images were taken using the JEOL 1010 microscope operated at 100 kV. Sample 
specimens were dispersed in ethanol and deposited on TEM copper grid and allowed 
to dry in air for a few seconds, before taking the images. 
 3.3.2 Scanning electron microscopy 
Scanning electron microscopy (SEM) was used to analyse the morphology and surface 
properties of the synthesised particles. SEM uses a focussed beam of high-energy 
electrons to generate various signals at the surface of the solid specimen giving us 
information about the texture (external morphology), crystalline structure and 
orientation of the materials of the specimen composition100.  We used a field emission 
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scanning electron microscope (FESEM, JEOL 7001) operated at 15kV in our studies. 
High-resolution scanning electron microscopy (HRSEM) images were obtained on 
JEOL JSM 7800 FE-SEM equipped with an in-column upper electron detector (UED) 
and gentle beam technology operated at a lower accelerating voltage of 0.8-1.5 kV.  
For SEM measurements, samples were prepared by dispersing the powder samples 
in ethanol after which they were deposited on to aluminium foil, attached to conductive 
carbon film on SEM stage. Then the prepared samples were kept for baking overnight 
in a vacuum oven at 70˚C before imaging. 
 
3.3.3 Nitrogen sorption measurements 
 Nitrogen adsorption measurements determined the investigations concerning the 
assessment of physical properties such as surface area, microporosity and 
mesoporosity, pore size distribution and pore volume of the particles. It measures the 
amount of nitrogen that adsorbs onto the subject of interest; regression analysis is then 
applied to the data resulting in the isotherm.  Nitrogen sorption isotherms of the 
samples were obtained at -196 °C using a Micrometrics Tristar II system. Before the 
measurements; the samples were degassed at 180 °C for 12 h in vacuum. The total 
pore volume was calculated from the amount adsorbed at maximum relative pressure 
(P/P0) of 0.99. The Barrett-Joyner-Halenda (BJH) method was used to calculate the 
pore size of samples from the adsorption branches of the isotherms. The Brunauer-
Emmett Teller 101 method a.k.a., BET was utilised to calculate the specific surface 
areas. 
 
3.3.4 Dynamic Light Scattering  
Dynamic light scattering  (DLS) usually referred to as a Quasi-Elastic Light Scattering 
(QELS)  was used in this PhD work to measure the size, size distribution as well as 
the level of polydispersity of the particles in aqueous solutions and culture media. DLS 
is a well- established technique that uses Non-Invasive Back Scattering (NIBS) 
technology, which detects the Brownian motion of the particles in the suspension 
causing the laser light to scatter at different intensities102.   The fluctuations in the light 
intensities vary according to the velocity of the Brownian motion of the particles within 
the suspension. The variations in the intensities are analysed, and the particle sizes 
are estimated using the Stokes-Einstein relationship103. The size of the particles was 
measured in nanometres whereas the polydispersity was measured in scales of PDI 
(Polydispersity Index). According to IUPAC recommendations, PDI is the "degree of 
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non-uniformity" of distribution of particles, where PDI=0.0 signifies perfectly uniform, 
PDI 0.0-0.1 signifies narrow monodispersion, PDI 0.1-0.4 signifies polydispersion. The 
hydrodynamic sizes of particle samples in this PhD project were measured using 
Malvern NanoZS Zetasizer at 25 ◦C in phosphate buffer solutions (PBS) and DMEM 
culture media. 
 
3.3.5 Elemental Analysis 
To analyse and quantify the elemental composition of the synthesised nanomaterials 
we used Elemental Analysis (EA). For this PhD project, we used CHNS-O Analyser 
(Flash EA 1112 series, Thermo Electron Cooperation) to determine the percentage of 
elements of carbon (C), nitrogen (N), hydrogen (H) and oxygen (O), according to the 
dynamic flash combustion (modified Dumas method). 
  
3.3.6 Raman Spectroscopy 
Raman spectroscopic techniques is a well-recognised practical method of chemical 
analysis and characterisation applications since the discovery of “Raman Effect” in 
1928 by renowned Indian physicist Sir C. V. Raman. We characterised our synthesised 
particles using Raman spectroscopic analysis to get more insight into the structural 
and chemical differences in different samples. Renishaw Raman Microscope and 
Spectrometer were used for the analysis, which has an accuracy of one wavenumber 
equipped with three laser wavelengths (325nm, 514nm and 785nm) for Raman 
vibrational analysis. 
  
3.3.7 X-Ray Photon Spectroscopy 
X-Ray Photon Spectroscopy (XPS) is an excellent, non-destructive spectroscopic 
technique to analyse the surface chemistry of particles104. In this PhD work, we used 
Kratos Axis Ultra photoelectron spectrometer with a monochromatic Al Kα (1486.6 eV) 
X-ray source to analyse our samples for surface chemical composition. Each spectrum 
was recorded at a survey scan from 0 to 1200 eV with a dwell time of 100 m, and pass 
energy of 160 eV at steps of 1 eV with one sweep.  
 
3.3.8 Electron Paramagnetic Resonance Spectroscopy 
Electron paramagnetic resonance (EPR) (or synonymously electron spin resonance 
(ESR)) is a magnetic resonance technique used to investigate materials with unpaired 
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electrons such as free radicals, transition metal ions and clusters. EPR analysis 
provides essential information that can be applied to studies of nanomaterials, 
materials science, biology, chemistry, food science, radiation dosimetry and medicine.   
EPR analysis was essential  to investigate the number of free radicals present   before 
and after the addition of the synthesised particles  to measure the free radical 
scavenging activity of  particles. Bruker Elexsys E580 Pulsed Q-, X-band (with high 
power microwave amplifiers) for variable temperature (1.5-300K) EPR / ENDOR / 
ELDOR / ESEEM / DEER Spectrometer was used to carry out the analysis for this 
work. 
 
3.3.9. Thermo Scientific™ Nicolet™ 6700 FT-IR 
spectroscopy  
Fourier transform infrared (FTIR) spectroscopy was utilised to trace the carbon 
bonding of different MCHS-T. The powder of samples was added merely onto the 
crystal to obtain optimal contact. FTIR spectra were collected using the Thermo 
Scientific™ Nicolet™ 6700 FT-IR spectrometers. Each spectrum was obtained using 
dried powder against a background measured under the same condition. For each 
spectrum, 128 scans were collected at a resolution of 4 cm-1 over the range 400–4000 
cm-1. 
 
3.3.10. UV-2450 Shimadzu Spectrophotometer  
 UV-2450 is a universal research grade spectrophotometer that can be used in a wide 
range of fields and can easily be expanded to suit the measurement objective.  It was 
used to measure the absorbance of spectra from 200 nm-900 nm with just one scan. 
It was used to measure the optical properties of nanoparticles. 
 
3.3.11. NanoDropTM 1000 Spectrophotometer 
NanoDrop-1000TM Spectrophotometer is full spectrum robust UV-Vis 
spectrophotometer used for quantification and evaluation of purity of samples such as 
proteins and nucleic acids. It has a full spectrum (220-750 nm). Spectrophotometer 
utilizes a patented retention technology that employs surface tension alone to hold the 
sample in place. This allows for the analysis of sample sizes as small as 0.5 μl. The 
high absorbance capability of the instrument is reported to be 50 times that of 
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traditional spectrophotometers.  In this thesis, the concentration of highly sensitive 
HSP protein inhibitors was measured using NanoDrop-1000TM Spectrophotometer to 
quantify the amount absorbed in the nanocarriers and the amount released in the 
solutions at different time points.  
 
3.4.12. TECAN Infinite® 200 PRO 
The Infinite®200 PRO is an efficient multi-mode, easy-to-use plate reader that offers 
high-performance detection solutions by monochromator- or filter based technologies.  
The readers offer up to six detection modes for sample measurements in 6- to 384-
well plates, PCR plates or cuvettes, based on the Quad4 Monochromators Infinite M 
and filter-based Infinite F configurations. Three sets of advanced optics and three high-
performance detectors – optimised for the requirements of fluorescence, 
luminescence and absorbance reading – allow uncompromised performance in all 
detection modes.  This detector is often used in various vital applications such as UV-
Viz detection, DNA/RNA/protein quantification absorbance based ELISA, 
chemiluminescent ELISAs and many more. 
 
3.4 Biological Characterisations 
3.4.1 Confocal Laser Scanning Microscopy 
Confocal Laser Scanning Microscopy (CLSM), an advanced imaging technique was 
used to obtain precise and clear images of biomaterials and the biological specimens. 
For this PhD project, ZEISS LSM 710 was used to capture the fluorescence of dye 
molecules loaded on the biomaterials and their cellular interactions.  ZEIS LSM 710 is 
a laser scanning confocal microscope with advanced imaging capabilities that offers 
high sensitivity and superior signal to noise ratio, which has 34 channel detectors to 
monitor changes of multiple fluorophores.  Bright field images were also obtained as 
the microscope can be flexibly selected with two flanking photomultipliers (PMT) 
channels and a 34 channel PMT array. 
3.4.2 Flow Cytometry 
 Flow cytometry is a favourite analytical technique in cell- biology that utilises light to 
count and profile cells and its complexity in a heterogeneous fluid mixture.  It is used 
extensively throughout life and biomedical sciences where researchers need to rapidly 
profile a large population of cells in media, forex, identifying, separating and 
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characterising immune cell subtypes by their size and morphology.  In this PhD, project 
the intracellular uptake of fluorescent-tagged carbon particles, protein delivery, and 
intracellular ROS levels were quantified using BD LSR-II Analyzer (USA). The results 
were analysed by FlowJo Software. 
 
3.4.3. MTT Assay 
 MTT assay involves using MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide, a yellow tetrazolium salt which gets reduced to purple formazan in living cells 
105. A solubilisation solution such as dimethyl sulfoxide (DMSO) is added to dissolve 
the insoluble purple formazan product into a coloured solution. The absorbance of this 
coloured solution is measured at a particular wavelength (usually between 490 nm and 
600 nm) by UV-Vis spectrophotometer. MTT assay is a well-established colourimetric 
assay for assessing cell metabolic activity.  In viable cells the NAD(P)H-dependent 
cellular oxidoreductase enzymes under defined conditions which reflects the number 
of viable cells present. These enzymes are capable of reducing the tetrazolium dye 
MTT to its insoluble formazan, which has a purple colour. In this PhD thesis, MTT 
assay was used to assess the cytotoxicity of nanocarriers delivering active bio/drug 
molecules into the cytosol of the cancer cells causing the ablation of cancer cells. 
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Chapter 4 
Mesoporous Carbon 
Hollow Spheres: 
Carbonisation-
Temperature-Dependent 
Delivery of Therapeutic 
Proteins 
 This chapter reports the influence of carbonization temperature of mesoporous carbon 
hollow spheres (MCHS) on their delivery performance of therapeutic protein.   This 
work has been published in Journal of Material Chemistry B, 2018; 5, 763-768. 
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4.1. Introduction 
Protein-based therapeutics are gaining increasing popularity for disease and cancer 
treatment because of their higher specific functions and fewer side effects over small 
molecule drugs.106, 107 However, the fragile structures and poor cell membrane 
permeability of therapeutic protein molecules have impeded the broad applications of 
protein therapeutics. Exploiting nanocarrier systems has revolutionised the therapeutic 
practices of protein molecules by overcoming these issues with enhanced therapeutic 
efficacy.8, 108 Various leading nanocarriers systems have been developed, including 
polymers, lipids, micelles, quantum dots, gold nanoparticles, mesoporous 
phosphosilicate nanoparticles and, carbon nanoparticles.108, 109 Recently, the pristine 
mesoporous carbon nanospheres have stood out as a promising candidate with 
advantages of large pore sizes, excellent safety profile and hydrophobic nature for 
efficient therapeutic protein loading.110  
Mesoporous carbon nanospheres are generally derived from the polymer sources 
under the heating process in a nitrogen environment,28 in which the treated 
carbonisation temperature determines the physicochemical (e.g. hydrophobicity and 
crystallinity), electrical and mechanical properties behaviour of final products.33, 23, 34, 
35 Studies were done which demonstrated that carbonisation temperature on carbon 
nanomaterials profoundly influenced their performance in fuel cells,83 catalyses,84 and 
gas separation.85 When using as nano-carriers for therapeutic protein delivery, it 
remains unknown what the effect of carbonisation temperature of mesoporous carbon 
spheres has on their delivery performance.  
Herein, for the first time, we reported the impact of carbonisation temperature of 
mesoporous carbon hollow spheres (MCHS) on their delivery efficiency of therapeutic 
proteins and correlated with physicochemical properties determined by carbonisation 
temperature. MCHS-T samples were prepared at various carbonisation temperature 
(T=500, 700, 900 C) and characterised. The carbonisation temperature difference, 
Δ°C, was kept at 200° C  as it played a significant role in terms of "replication" (a classic 
statistical definition of an intervention or treatment) in experimental units111.  Trial tests 
with several temperature differences  ranging from, Δ°C, 50° C to 200° C,  we observed 
that 200° C is the minimum temperature change the nanoparticles needed to acquire 
the morphological, structural and physicochemical variations to determine the 
contribution of carbonisation temperature in delivery efficiency in cell culture studies 
and acquire statistical significance.  It was found that the pore size, pore volume and 
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hydrophobicity of MCHS increased as T increasing, mainly from 500 to 700. RNase A 
was chosen as a model of therapeutic proteins. MCHS-900 possess the highest 
loading capacity and most sustained release of RNase A, contributed by the high 
hydrophobicity and large pore size. RNase A delivered by MCHS-900 showed the best 
therapeutic efficacy with significant inhibition of human squamous carcinoma cells 
(SCC25), comparing to free RNase A or those delivered by MCHS-500 and MCHS-
700. Also, MCHS-900 significantly promoted intracellular delivery of RNase A and 
subsequent endo/lysosome escape in SCC25 comparted to the other MCHS carriers, 
which are crucial for protein therapeutics.  
 
 
Scheme 4.1.  Schematic representation of mesoporous carbon hollow spheres optimised by 
carbonization temperature for intracellular therapeutic protein delivery and the cancer cell cytotoxicity. 
4.2. Experimental section 
4.2.1. Characterizations  
Transmission Electron Microscopy images were taken using a JEOL 1010 microscope 
operated at 100 kV. The TEM specimens were dispersed in ethanol and then 
transferred to a copper grid. For Scanning electron microscopy (SEM) measurements, 
the samples were prepared by dispersing the powder samples in ethanol, after which 
they were dropped to the aluminium foil pieces and attached to conductive carbon film 
on SEM mounts. The SEM mounts were heated in a vacuum oven at 70 °C for at 8 
hours before observations. Nitrogen sorption isotherms of the samples were obtained 
at -196 °C using a Micromeritics Tristar II system. Before the measurements, the 
samples were degassed at 180 °C overnight in vacuum. The BET surface area was 
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calculated using experimental points at a relative pressure of P/P0 = 0.05- 0.25. X-ray 
photoelectron spectroscopy (XPS) analysis was conducted using a Kratos Axis 
ULTRA X-ray photoelectron spectrometer. Peak fitting was carried out using the Casa 
XPS software. Elemental analysis (EA) was performed with a CHNS-O Analyzer (Flash 
EA1112 Series, Thermo Electron Corporation). The Raman analysis was done using 
the Renishaw Raman microscope. The particle size distribution profiles were collected 
at 25 °C using a Zetasizer Nano-ZS from Malvern Instruments. 
4.2.2. Loading and Release Study 
RNase A loading test was measured using “Bradford Protein Assay” (a spectroscopic 
analytical technique). Firstly, a stock solution of 2 mg mL-1 of RNase A was prepared 
in a PBS buffer solution. 1 mg of MCHS-T was dispersed in a 0.5 mL of PBS and 
ultrasonicated for 5 min to disperse MCHS-T in the solution thoroughly. Then 1.5 mL 
of RNase A stock solution was added to MCHS-T previously dispersed in PBS, in a 
2mL Eppendorf tube. The tubes were kept in an incubator shaker for 24 h, shaken at 
a speed of 200 rpm, maintained at a temperature of 25°C in the dark. After the 
designated time, the tubes were centrifuged at 15000 rpm after which the supernatant 
was collected for spectrophotometric analysis. The collected supernatant was treated 
with Bradford reagents, and the concentration of RNase A was measured in a UV-Vis 
spectrophotometer at 277.5 nm. The decrease in concentration of protein was 
indicative of protein adsorption capacity. The release study was conducted by re-
suspending the residual precipitate in fresh PBS solution and shaken in the incubator 
shaker at 200 rpm at 37 °C.  The tubes were collected at specific intervals, centrifuged 
at 15000 rpm while 1 mL of the supernatant was replaced with fresh PBS solution. The 
protein concentration in the supernatant was determined by the same method to 
calculate the cumulative release profile. 
4.2.3. Media preparation 
The human squamous carcinoma (SCC 25) cells were grown in complete Dulbecco's 
modified Eagle's medium and Ham's F12 medium (DMEM/F12), supplemented with 
fetal calf serum (10%, FCS), L-glutamine (1%), penicillin-streptomycin (10,000 U mL-
1), 0.5 mM sodium pyruvate and 400 ng/mL hydrocortisone. For subculturing purposes, 
the cells were washed with sterile PBS solutions and trypsin (0.25 g L-1). The cells 
were attached to T75 flasks and incubated at 37 °C under 5% CO2 sterile environment. 
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4.2.4. Toxicity Assay 
Cellular toxicity assay of MCHS-T was conducted after exposing the carcinoma cells 
with loaded RNase A, incubating for a required period and counting the viable and 
non-viable cells using haemocytometer. SCC-25 cells were seeded in a 24-well plate 
at a density of 0.05 x 106 cells/well. Then the cells were incubated overnight at 37 °C. 
After the overnight incubation, the cells were treated with a solution of MCHS-T loaded 
with RNase A, where the final concentrations of the loaded RNase A were 10, 25 and 
50 µg mL-1. To evaluate the cytotoxicity of carbon spheres, they were diluted in 2-fold 
series in the culture medium and incubated for 24 and 72 h. The safety of the pure 
MCHS-T was elucidated by treating SCC25 cells to 10, 25 and 50 µg mL-1 of bare 
MCHS-T as negative controls. After 24 and 72 h, the culture medium from each sample was 
collected, and cells were detached by incubating with 100 µL of 0.25% trypsin/EDTA mixture. 
Detached cells were then mixed with the medium previously collected from the sample. The 
cell suspension was diluted with Trypan Blue reagent in a 1:1 ratio. Live and dead cells were 
counted on a "haemocytometer". Cell viability was calculated using the following formula: 
 Cell viability (%) = [viable (live)cell count]
[Total (live+dead)cell count]
∗ 100 
4.2.5. Confocal imaging 
SCC25 cells were seeded on sterile glass coverslips kept a 6-well plate (Nalge NUNC 
International, Rochester, New York) at a seeding density of 1.5 x105 cells per well and 
cultured overnight at 37 °C in DMEM/F12 media. Simultaneously FITC conjugated 
RNase A (FITC-RNase A) was loaded in MCHS-T particles (FITC-RNase A@MCHS-
T) following the same process as described in the protein loading section, at a feeding 
ratio of 2:1. The loading was estimated by detecting the change fluorescence using 
TECAN Infinite 200 Pro. FITC-RNase A@MCHS-T samples along with the control 
group (RNase A in PBS) were added to the culture media at a final RNase A 
concentration of 25 µg mL-1. One set of cells were incubated for 1 h whereas the 
second set for 6 h at 37 °C. Afterwards, the media was removed, and the cells were 
washed with sterile PBS. After adding fresh serum-free media, Lysotracker Red DND-
99 was added at a concentration of 50-75 nM in the media. The cells were incubated 
for 30 min at 37 °C, then washed twice with PBS. The sterile glass coverslips were 
treated with 0.5 mL of 4% w/w paraformaldehyde solution to fix the cells followed by 
incubation overnight at room temperature. In the end, images were taken using the 
Zeiss LSM 710 META confocal microscope (Carl Zeiss, Thornwood, New York).  
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4.3. Results and discussions 
MCHS-T samples were synthesised using silica templating method via a one-pot 
synthesis method. SEM images of MCHS-500, MCHS-700 and MCHS-900 are shown 
in Fig 4.1A-C, respectively. MCHS-500 displays an aggregated, non-uniform and 
partially concaved spherical morphology (Fig 4.1A). In contrast, MCHS-700 and 
MCHS-900 both show spherical morphologies with uniform particle sizes of  170 nm 
in diameter (Fig 4.1B and C). The structural differences in MCHS-T samples were 
examined using TEM. MCHS-T samples all exhibit a hollow spherical structure, owing 
to their formation mechanism as reported previously.28, 75 However, the TEM image of 
MCHS-500 indicates that the wall of hollow spheres is deformed or partially collapsed 
(Fig 4.1D), consistent with the SEM observation in Fig. 1A. Moreover, the mesopores 
within the wall are not evident. For MCHS-700 (Fig 4.1E) and MCHS-900 (Fig 4.1F), 
the intact hollow spherical morphology and the mesopores in the wall are clearly seen. 
Collectively, both SEM and TEM results have demonstrated that the carbonisation 
temperature has a significant impact on the final structure of MCHS-T samples. 
 
  Fig 4.1 SEM (A, B, C) and TEM (D, E, F) images of MCHS-500, MCHS-700 and MCHS-900, 
respectively.  
To understand the influence of carbonisation temperature on the composition and 
structure of MCHS-T samples, XPS and EA analyses were conducted, and the results 
are summarised in Table 4.1. MCHS-500 has the highest oxygen content of  9.47% 
followed by MCHS-700 (5.09%) and MCHS-900 (4.48%). This trend is the same for 
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the H content in MCHS-T samples. For the carbon content, MCHS-500 shows the 
lowest value of 76.44% while MCHS-700 and MCHS-900 have a similar carbon 
content of 84 %. The above results indicate that the carbon content in MCHS-T 
samples increases with the carbonisation temperature, especially in the relatively low-
temperature range (500-700 °C). The increase in carbon content is accompanied by a 
decrease in the O and H contents when the carbonisation temperature increases. It is 
noted that the oxygen content was measured by XPS, which generally reflects the 
surface composition difference. FTIR analysis also aligned with The XPS, and EA data 
obtained. FTIR analysis showed an absence of hydroxyl groups in MCHS-700 and 
MCHS-900 which can be attributed to the low O and H content (as provided in 
supporting information; Fig 4.S.2). Even MCHS-900 has a similar C content to MCHS-
700 (measured from EA), the relatively lower O content leads to higher hydrophobicity 
as measured by the Rose Bengal adsorption test (Fig 4.S1). 
   Fig 4.2. Raman spectra (A) and DLS profiles of MCHS-T (B) in PBS and (C) in DMEM culture 
media. 
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Raman analysis was conducted to investigate the influence of carbonisation 
temperature on the atomic structures of MCHS-T samples. As shown in Fig 4.2A, the 
Raman spectra of three samples exhibit both the "G band" (graphitic band) centred at 
1580 cm-1 "D bands" (disordered band) centred at 1357 cm-1.112, 113 The ratio between 
the intensities of the D band and G band, i.e. ID/IG, is an important measurement of 
sp3/sp2 bonded carbon atoms.114 With the increase in carbonisation temperature (500, 
700, 900 °C), the ID/IG values increase (0.63, 0.81, 0.92). This observation is a common 
phenomenon in phenolic resins,35, 115,86 indicating the ratio of disordered carbon atoms 
increases at elevated temperature. Moreover, MCHS-700 and MCHS-900 display 2D 
(G') peaks characteristic of multilayer graphene,86 which is absent in MCHS-500, 
suggesting that graphitization starts at carbonisation temperature higher than 700 °C.  
The dispersion of MCHS-T samples in phosphate buffer solution (PBS, pH 7.0) and 
DMEM media was analysed using DLS analytical technique. The DLS profiles of 
MCHS-700 and MCHS-900 show a narrow size distribution centred at 210 nm with a 
low polydispersity index (PDI) of 0.1 in PBS (Fig 4.2B). MCHS-500 shows a broad size 
distribution at 290 nm with a PDI of 0.4, indicating an aggregated structure. The 
dispersion of MCHS-T under aquatic conditions is influenced by its composition.116-118 
The aggregation of MCHS-500 is attributed to its higher oxygen content than MCHS-
700 and MCHS-900. For MCHS-700 and MCHS-900 with a higher degree of 
carbonisation and increased hydrophobicity, their dispersity in PBS is significantly 
improved. However, at an even higher carbonisation temperature such as 1100 °C 
(MCHS-1100 in Fig 4.S3A), surface oxygen content decreases further to 3.32%. The 
sample MCHS-1100 forms visible aggregates due to high hydrophobicity (Fig 4.S4), 
suggesting low colloidal stability of MCHS-1100.  
The colloidal stability of MCHS-T was also measured in DMEM (a cell culture 
medium) using DLS. As shown in Fig 4.2C, MCHS-900 is well dispersed in DMEM with 
a uniform size of 210 nm and a low PDI value of 0.13. For MCHS-700, the size 
increases from 210 nm in PBS to 260 nm and the PDI changes from 0.1 in PBS to 0.4. 
MCHS-500 has a broad size distribution centred at 290 nm and a high PDI of 0.93, 
indicating highly aggregated particles. This phenomenon has been observed in the 
previous studies,28 in which the biomolecules in a cell culture medium may be 
absorbed on the carbon spheres.  Our studies have shown that MCHS-900 has 
excellent colloidal stability in PBS and DMEM, which is crucial for cellular delivery 
applications. 
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Nitrogen adsorption isotherms of MCHS-T samples are shown in Fig 4.3A. MCHS-
700 and MCHS-900 exhibit a type IV isotherm with two capillary condensation steps 
occurring at P/P0 = 0.6-0.7 and P/P0 >0.9, characteristic of mesopores and large cavity, 
respectively. Compared to MCHS-700 and MCHS-900, MCHS-500 exhibits limited 
porosity and a large hysteresis loop indicating small pore entrance. The pore size 
distribution curves calculated from the adsorption branch using 
Barrett−Joyner−Halenda (BJH) model are shown in Fig 4.3B. The pore size of MCHS-
500, MCHS-700 and MCHS-900 is 3.8, 6.0 and 6.9 nm, respectively. The Brunauer− 
Emmett−Teller (BET) surface area and pore volume of MCHS-T are summarised in 
Table 1. Compared to MCHS-900, MCHS-700 has a slightly higher surface area (1,705 
vs 1,550 m² g-1) and pore volume (2.8 vs 2.6 cm3 g−1) due to the slight framework 
shrinkage at a higher temperature.115 MCHS-500 has the smallest surface area (494 
m2 g−1) and pore volume (0.7 cm3 g−1). Our results have shown that the carbonisation 
temperature has a significant impact on the pore structures of MCHS-T samples. It is 
suggested that at a low carbonization temperature of 500 °C, the polymer network is 
not rigid and may deform during the silica etching process. Thus, the created 
mesopores are partially collapsed, leading to the low surface area and pore volume119. 
MCHS-1100 shows a similar porosity with MCHS-900 (Fig 4.S3B). 
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Fig. 4.3. (A) N2 adsorption-desorption isotherms, (B) pore size distribution curves, (C) loading capacity 
of RNase A and (D) RNase A release profiles of MCHS-T. 
Table 4.1. Summary of the physicochemical properties of MCHS-T 
Sample S 
(m2 g-1) 
P 
(nm) 
V 
(cm3 g-1) 
C% H% O% 
MCHS-500 494 3.8 0.7 76.44 3.62 9.47 
MCHS-700 1705 6.0 2.8 84.17 1.92 5.09 
MCHS-900 1550 6.9 2.6 84.02 1.42 4.48 
 
 Note: S is BET surface area, P is pore size, V is total pore volume, C% is carbon percentage, H% is 
hydrogen percentage, and O% is oxygen percentage.  
Ribonuclease A (RNase A) with a size of 2.2 × 2.8 × 3.8 nm and a hydrophobic 
domain,120 was reported as a potent therapeutic protein for cancer treatment by 
degrading cellular RNA and inhibiting protein production in the cytosol.  RNase A was 
52 
 
chosen as a model protein to evaluate the delivery performance of MCHS-T.  RNase 
A loading and release profiles were measured for MCHS-T before therapeutic 
evaluation. As shown in Fig 4.3C, MCHS-900 has the highest loading capacity among 
three MCHS-T samples. Moreover, MCHS-900 shows the slowest release, with  40% 
of RNase A released in a period of 48 h (Fig 4.3D). 
The high loading capacity and sustained release of MCHS-900 compared to two other 
samples are attributed to its high hydrophobicity as well as the large surface area and 
porosity. Based on our calculation (Table 4.S1 and Additional Discussion in supporting 
information), it is deduced that RNase A molecules loaded in MCHS-700 and MCHS-
900 are mainly located on the mesoporous walls rather than the inner hollow cores. 
MCHS-1100 treated at even higher carbonization temperature demonstrates 
significantly decreased RNase A loading capacity (Fig 4.S5a) and slightly more 
sustained release (Fig 4.S5b) comparing to MHCS-900. High hydrophobicity induced 
aggregates of MCHS-1100 may hinder RNase A diffusion into the carbon samples in 
aqueous solutions. Furthermore, the large aggregates also significantly reduce cellular 
uptake of MCHS-1100 comparing to MCHS-900 (Fig 4. S5 c, d). It has been reported 
that efficient cellular uptake and high loading are crucial for therapeutic protein 
efficacy.121  Thus, MCHS-1100 is not included in the following studies.  
The cytotoxicity tests of MCHS-T and RNase A loaded MCHS-T were conducted in a 
cancer cell line (SCC25). For pure carriers as a negative control, there is little toxicity 
after the first 24 h of incubation at a high dose of 200µg mL-1 (Fig 4.S6). However, after 
further incubation for 48 h, MCHS-500 shows a higher level of toxicity with cell viability 
of  70% due to its high organic content, which causes cellular irritation. MCHS-700 
and MCHS-900 mostly comprised of inert carbon are biocompatible, but after 48 h 
MCHS-700 shows slight toxicity ( 85% cell viability), whereas MCHS-900 retains its 
inertness. These results suggest that MCHS-900 is the most biocompatible carriers 
among the three tested samples.    
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Fig. 4.4  Dosage-dependent cell viability of SCC25 cells treated with bare and RNase A after (A) 24 
and (B) 48 h incubation. ns p> 0.05, *p<0.05, **p<0.01, ***p<0.001. 
SCC25 cells were exposed to various concentrations of RNase A@MCHS-T where 
the final concentration of RNase A was 10, 25 and 50 µg mL-1. Untreated cells were 
used as a blank control while both bare particles and naked RNase A were included a 
control with the same concentrations. Figs. 4A and B represent the dose-dependent 
cytotoxicity at 24 and 48 h incubation, respectively. In the first 24 h, 74.4% of cells 
are inhibited by MCHS-900@RNase A at the highest dosage of 50 µg mL-1, 
significantly better than MCHS-700@RNase A (57.8% inhibition), MCHS-500@RNase 
A (37% inhibition) and naked RNase A (38.2% inhibition) at the same dosage. After 
incubation for 48 h, the inhibition ratio is up to 93.9%, 86.7%, 36.9% and 29.4 % for 
MCHS-900@RNase A, MCHS-700@RNase A, MCHS-500@RNase A and free 
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RNase A groups at 50 µg mL-1, respectively. In this prolonged incubation period, the 
anticancer efficiency of RNase A delivered by MCHS-900 and MCHS-700 significantly 
improved; however; in the case of MCHS-500, the therapeutic effect remains similar. 
The cytotoxicity tests demonstrate that the carbonisation temperature has a significant 
influence on the cellular delivery efficacy of RNase A for cancer cell treatment.  
 
 
Fig. 4.5 Confocal microscopy images of SCC25  treated with RNase A delivered with MCHS-700 and 
MCHS-900. Blue fluorescent signal indicates the nuclei stained with DAPI; green represents FITC 
tagged with RNase A and red represents the endo/lysosome stained by lysotracker.  Scale bar is 10 
m. 
 
Efficient cellular uptake and endo/lysosome escape ability are essential for successful 
intracellular delivery of therapeutic proteins to achieve their functions inside cells.108 
To further understand why MCHS-900 has the best cellular delivery efficacy, the cells 
incubated with the MCHS-T samples loaded with RNase A tagged with FITC (RNase 
A@FITC) were monitored using the confocal microscope. The subcellular 
compartments of endo/lysosomes were traced using Lysotracker Red. As shown in 
Fig. 5, the green fluorescence intensity in SCC25 cells is much stronger in the MCHS-
900 group compared to MCHS-700, indicating promoted intracellular delivery of 
RNase A. However, MCHS-500 has undetectable green fluorescence (Fig. S6). For 
MCHS-700, a significantly higher number of RNase A co-localized with endosomes 
(indicated by yellow fluorescence with triangle symbols) was observed compared to 
MCHS-900, suggesting that MCHS-900 is more efficient in endo/lysosome escape, 
contributed by improved hydrophobility.122 Hydrophobic nanoparticles have been 
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reported to improve cellular uptake and facilitate cytosol delivery of therapeutic 
proteins with significantly enhanced cancer treatment efficacy.122 These results 
indicate that MCHS-900 having the highest hydrophobicity demonstrate the best 
cellular uptake and most successful cytosol delivery of RNase A. 
4.3. Conclusions 
In summary, MCHS-T samples were synthesised under carbonisation temperature at 
500°C (MCHS-500), 700°C (MCHS-700) and 900°C (MCHS-900) to evaluate their 
intracellular delivery performance of therapeutic proteins. MCHS-900 showed the 
highest hydrophobicity among all samples, exhibiting superior RNase A (a model of 
therapeutic proteins) adsorption and sustained release, beneficial for therapeutic 
protein delivery. RNase A delivered by MCHS-900 demonstrated significantly 
improved anti-cancer efficacy than free RNase A or delivered by MHCS-500 and 
MHCS 700. Furthermore, MCHS-900 also enhanced the cellular uptake of RNase A 
and successful endosomal escape, critical steps for therapeutic protein delivery. 
These findings in this work provide the rational design of efficient carriers with 
enhanced therapeutic protein delivery performance.   
4.4. Supporting Information 
4. S.1. Synthesis of MCHS-T 
Mesoporous carbon hollow spheres (MCHS) were synthesised according to our 
previously reported method.75 Specifically, 12 mM of tetrapropyl orthosilicate (TPOS) 
was added into an alcoholic solvent system consisting of 70 mL of absolute ethanol 
and 10 mL of deionized water with 3 mL of ammonium hydroxide (28 wt %) as a 
catalyst. Then, the above mixture was stirred for 15 minutes at room temperature, 
followed by simultaneous addition of 0.4 g of resorcinol and 0.56 mL of formalin (37 
wt. %). The reaction solution was continuously stirred for 24 hours. The resultant slurry 
was collected and subjected to high-speed centrifugation at 20,000 rpm for 15 minutes. 
The solid samples were collected after washing with ethanol for three times and then 
dried overnight at 50 °C overnight.  The hybrid RF polymer/silica samples were 
carbonised at different temperatures (500, 700, 900 or 1100 C) for 5 hours under a 
nitrogen environment. The samples were then treated with 10 % hydrogen fluoride 
(HF, 50 %) solution for at least 24 hours to remove silica templates and washed 
thoroughly with deionized water three times. Finally, the carbon samples were 
obtained after drying at 50 °C overnight and denoted MCHS-T (T= 500, 700, 900, 
1100), where T  represents the carbonisation temperature in a nitrogen environment. 
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4. S.2. Fourier transform infrared spectroscopy (Fig 4.S) 
Spectral analysis of MCHS 
 
Fig 4.S1. FTIR spectral analysis of MCHS-T carbonised at different temperatures indicated as MCHS-
500, MCHS-700, and MCHS-900. 
 FTIR spectra of mesoporous carbon nanocarriers (MCHS) were conducted to identify 
the conformational differences in the samples carbonised at three different 
temperatures, presented in Fig. 4.S1. In the recorded spectra, a band around 3500-
3400 cm-1 range were observed indicative of O-H stretching vibrations in MCHS-500, 
which were absent in MCHS-700 and MCHS-900.  This showed that MCHS carbonised 
at lower temperature had hydroxyl groups present in the nanoparticles structures that 
got removed when carbonised at a higher temperature>700°C and above. Moreover, 
MCHS-500 showed sharp band around 1597 cm-1. One of the possibilities could be 
indicative of the presence of N-H amine bonds, conceivably due to the addition of 
ammonium hydroxide in the system to maintain a basic condition for the TPOS 
hydrolysis, which is not observed in MCHS-700 as well as MCHS- 900. However, no 
N-H stretching band for ammonium at 3100 cm-1 can be observed. Therefore, we 
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believe this band can be assigned to C=O bonds from residual and not fully carbonised 
resorcinol, which diminished at a higher temperature. A medium, broad peak around 
1200 cm-1 suggested the presence of C-O bond in MCHS-500, while in case of MCHS-
700, the peak intensity was significantly diminished while being completely absent in 
MCHS-900. It is interesting to notice subtle peaks around 1100 cm-1 and 1047 cm-1 in 
MCHS-700 suggesting a shift of band to lower wavenumber which indicates the 
conversion of C-O bonds into C-C bonds 123. A band peak around 1550 cm-1 in MCHS-
700 indicated C=C bond stretching usually connected to the vibration of aromatic 
structures 124. As the carbonization temperature increased to 900 °C in MCHS-900, 
the intensity of the peak for C=C decreased, indicating less polar functional groups. 
Apart from this intriguing trend, additional trend was observed from the spectra; three 
consecutive signalling peaks around 877 cm-1, 809 cm-1 and 752 cm-1 representatives 
of a sequence of C-H bonds in MCHS-500 were almost reduced to minimal in MCHS-
700 whereas almost non-existent in MCHS-900, thus, suggesting absence of any 
significant hydrogen bonds in the samples carbonized at higher temperatures. These 
observations support the theory of polarised hydrophobicity for samples carbonised at 
higher temperatures and as the temperature of carbonisation decreases, so does the 
hydrophobicity, as bonds with oxygen (O) persists at lower temperature modules. 
Clearly, from the FTIR peaks, it could be suggested, with increasing carbonisation 
temperatures, there was a significant decrease in functional groups indicating 
increased hydrophobicity, also supported by further Elemental Analysis (EA). 
4.S.3. Flow cytometry analysis to evaluate cellular uptake 
of MCHS-900 and MCHS-1100 
The cellular uptake of MCHS-900 and MCHS-1100 was estimated using flow 
cytometry analysis. Before the cellular study, 5µg of Rhodamine B Isothiocyanate 
(RBITC) was completely absorbed in 1 mg of MCHS-900 and MCHS-1100 in 1.5 ml of 
PBS, washed and resuspended in sterile PBS solution. SCC25 cells were seeded in a 
24-well plate with a density of 5104/well and incubated for 24 hours.  Afterwards, 25 
µg of RBITC@MCHS-900 or RBITC@MCHS-1100 were added in serum-free DMEM-
F12 media. The cells were incubated for 4 hours, and the media was then removed, 
and the cells were washed with PBS twice. Then the cells were harvested by treating 
the cells with trypsin, followed by washing with PBS. The cells were suspended in 4 % 
paraformaldehyde solution for 30 minutes at room temperature, washed again and 
then resuspended FACS buffer (0.5 % BSA with 5 mM of EDTA in PBS). 
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4. S.4. Hydrophobicity Test (Rose Bengal Partitioning test) 
The hydrophobicity of MCHS-T samples was evaluated using a xanthene dye “Rose 
Bengal” which preferentially gets adsorbed based on the hydrophobicity of the 
nanoparticles. It is a very reliable method, mainly applied in pharmaceutical studies to 
determine the surface hydrophobicity of nanoparticle drug delivery systems125. At first, 
in 0.1 M phosphate buffer solution (PBS) with a pH of 7.4, Rose Bengal (RB) reagent 
was dispersed making an aqueous RB stock solution. The stock solution was diluted 
to obtain a final concentration of 20 μg/mL. Then the dye solutions were added to 
various concentrations of nanoparticles (MCHS-T), followed by incubation at 25°C for 
3 hours. Afterwards, the suspensions were centrifuged at 13,300 rpm for 10 minutes. 
The supernatants were collected, and absorbance was measured using UV-Vis 
spectroscopy at 549 nm. Evaluation of hydrophobicity by adsorption of RB was done 
by determining the PQ (partition quotient). PQ was plotted against the various 
concentrations of MCHS-T to indicate the ratio of an amount of RB [bound] to the 
MCHS-T Vs the RB [free] in the solution, where,  
 
𝑅𝐵 [𝑏𝑜𝑢𝑛𝑑]  =  [𝑅𝐵] 𝑡𝑜𝑡𝑎𝑙 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 −  𝑅𝐵 [𝑓𝑟𝑒𝑒]  
 
Moreover, PQ is calculated as:  
𝑃𝑄 =  𝑅𝐵 [𝑏𝑜𝑢𝑛𝑑]/ 𝑅𝐵 [𝑓𝑟𝑒𝑒]  
 
The degree of RB entrapment is expressed through the loading capacity and loading 
efficiency values. Loading capacity (LC) takes the amount of RB entrapped in the 
particles as a function of the weight of particles. Loading efficiency (LE) is calculated 
by comparing the amount of RB included in the particles with the total sum of RB. The 
following equations determined loading capacity (LC) and loading efficiency (LE):  
 
𝐿𝐶 (%) = 𝐵𝑜𝑢𝑛𝑑 [𝑅𝐵]/𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 × 100  
  
𝐿𝐸 (%) = 𝑏𝑜𝑢𝑛𝑑 [𝑅𝐵]/𝑡𝑜𝑡𝑎𝑙[𝑅𝐵] × 100  
 
Three batches of particles were prepared in each system, and the results are given as 
average and standard deviations126. 
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Fig 4.S2. Relative hydrophobicity as measured by adsorption of Rose Bengal on MCHS-T. (A) PQ and 
(B) LE values as a function of the weight of MCHS-T and (C) LC of 10 μg of MCHS-T towards RB.  
PQ values are shown in Fig 4.S2A showed a higher inclined slope in MCHS-900 
(0.140) than MCHS-700 (0.015) and MCHS-500 (0.002), suggestion more adsorption 
of RB per unit weight. LE values varied from 37 % to 80 % for MCHS-900 when the 
weight of MCHS-900 increased from 5 to 30 g (Fig 4.S2 B). In contrast, the LE value 
for MCHS-700 ranged from 0% to 30 % while that value for MCHS-500 could only 
reach maximum 6.9 % of LE given the highest amount of nanoparticles. The evaluation 
of LC was calculated based on 10μg of MCHS-T in aqueous RB solution. MCHS-500 
had the lowest capacity, 3.6 % followed by MCHS-700 with a value of 16.5%. MCHS-
900 was proved to have a much higher LC value (94 %) than the other two samples 
as shown in Fig 4.S2 C. These results consistently indicate that MCHS-900 have the 
highest hydrophobicity. Higher carbonisation temperature leads to higher 
hydrophobicity.  
 
Fig 4.S3. (A) TEM image and (B) nitrogen absorption-desorption isotherm and pore size distribution 
curve (inset) of MCHS-1100.  
TEM image of MCHS-1100 (Fig 4.S3A) reveals a similar intact hollow spherical 
morphology with the mesoporous wall as observed in MCHS-900.  The adsorption-
desorption plot (Fig 4.S3B) is typical type IV isotherm with one capillary condensation 
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step at P/P0=0.6-0.7, indicating mesoporous structure. The corresponding pore size 
distribution curve (inset of Fig 4.S3B) shows a pore size centred at 6.84 nm, which is 
similar to MCHS-900. BET surface area and pore volume of MCHS-1100 is 2145.5 
m2/g and 2.9 cm3g-1, respectively.  
 
 
Fig 4.S4. Images are showing the dispersion of MCHS-900 and MCHS-1100 after ultra-sonication. We 
observed that MCHS-900 had excellent dispersity in PBS buffer solution whereas MCHS-1100 started 
to separate from the buffer solution and settle as aggregates in PBS after 5 minutes of ultra-sonication. 
4. S.5. Additional Discussion:  Possible locations of RNase 
A molecules in MCHS samples 
To predict the possible locations of RNase A adsorbed on MCHS samples, RNase A 
adsorption capacity per unit surface area (mg/m2) is calculated (as shown in Table 
4.S1), dividing loading capacity by BET surface area excluding the unusable micropore 
area for RNase A adsorption. MCHS-500 has limited porosity. Thus RNase A 
molecules are mainly adsorbed on the external surface, showing a loading capacity of 
0.14 mg/m2. For MCHS-700 and MCHS-900, the pore size is 6-6.9 nm, which is smaller 
than double size of 3.8 nm (the largest dimension of single RNase A molecule). 
Therefore, it is unlikely that the single mesoporous channel on the shell could 
accommodate two RNase A molecules. In this case, the mesoporous area of MCHS-
700 and MCHS-900 is partially used for RNase A adsorption (around 50% or less), 
thus showing relatively low loading capacity of 0.06 and 0.09 mg/m2 for MCHS-700 
and MCHS-900. If RNase A molecules are loaded inside the large hollow cavity of 
MCHS-700 and MCHS-900, these molecules should in a multi-layer adsorption model 
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and the calculated RNase A adsorption capacity per unit surface area would be 
significantly higher than 0.06 or 0.09 mg/m2. Based on these results, we assume that 
RNase A molecules loaded in MCHS-700 and MCHS-900 are on the surface of carbon 
materials (mesoporous, external and internal wall) with a mono-layer adsorption 
model, rather than inside of hollow cores.   
 
 
Fig 4.S5. (a) Loading capacity of RNase A, (b) RNase A release profile of MCHS-900 and MCHS-
1100, (c) RBITC positive cell percentages and (d) mean fluorescence intensity of SCC25 cells treated 
with RBITC labelled MCHS-900 and MCHS-1100. 
MCHS-1100 shows a much lower RNase A loading capacity than MCHS-900 (0.065 
vs 0.117 mg/mg, Fig 4.S5a) and slightly more sustained release of RNase A (Fig 
4.S5b). To quantify the cellular uptake performance of MCHS-900 and MCHS-1100, 
flow cytometry was performed in SCC25 cells treated with RIBTC loaded carbon 
samples. The cells treated with RBITC loaded MCHS-900 show significantly larger 
proportion of RBITC positive cells (18.0±2.6% vs 14.4±0.9%, Fig 4.S5c) and stronger 
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mean fluorescence intensity (1550±91 vs 971±176, Fig 4.S5d) than those treated with 
RBITC loaded MCHS-1100. These results suggest that the low colloidal stability 
caused by high hydrophobicity significantly impedes the cellular uptake of MCHS-
1100, thereby not suitable for cellular delivery of RNase A.  
 
Fig 4.S6. Cell viability of SCC25 cells treated with bare MCHS-T at a high concentration of 200µg/mL 
to investigate the biocompatibility of the nanocarriers. 
 
Fig 4.S7. Confocal Microscopic images of SCC25 showing the fluorescent signals of blue representing 
DAPI and green representing RNase A tagged with FITC carried inside the cells by MCHS-500, the 
scale bar is 10m.  
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Table 4.S1. Calculated RNase A adsorption capacity of MCHS samples. 
 MCHS-500 MCHS-700 MCHS-900 
SBET (m 2 g −1 ) 494 1705 1550 
SMicro (m 2 g −1 ) 40 231 217 
SBET-Micro (m 2 g −1 ) 454 1474 1333 
CRNase A (mg g −1 ) 63.6 89.9 117 
C′RNase A (mg m −2 ) 0.14 0.06 0.09 
 
SBET (m 2 g −1 ): BET surface area; SMicro (m 2 g −1 ): t-Plot micropore area; SBET-Micro (m 2 g −1 ):BET surface 
area – t-Plot micropore area; CRNase A (mg g −1 ) : RNase A adsorption capacity; C′RNase A: RNase A 
adsorption capacity per m 2 (C RNase A/S BET-Micro).  
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Chapter 5 
Antioxidant property of 
pristine mesoporous 
carbon hollow spheres 
(MCHS) for ROS-mediated 
cancer therapeutic 
strategy  
This chapter reports the ability of MCHS to relieve intracellular oxidative stress, mainly 
prevalent in cancer cells, by its efficient free radical scavenging property.   Here we 
measured the antioxidant property of MCHS carbonised at varied temperatures to 
select the optimized MCHS for maximum scavenging activity.  We also tested the free 
radical scavenging activity of MCHS compared to other popular carbon scavengers to 
compare its effectiveness.   
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5.1. Introduction 
 The key to developing novel and effective cancer therapeutics is to understand the 
behaviour of cancer cells and their specific alterations. Mounting evidence has 
suggested that compared to healthy cells, most of its cancer counterparts have 
particular biochemical modifications that allow them to have high levels of intracellular 
ROS aka. “Reactive Oxygen Species”127, 128. ROS, are defined as highly reactive free 
radicals that arise from cellular respiration as essential by-products originating from 
the mitochondrial electron transport chain (ETC), found in almost all cells and tissues. 
They help in various critical biological functions such as signal transduction for the 
regulation of protein and transcription factors, cellular growth, survival and 
differentiation, vascular regulation, oxygen sensing for initiating adaptive responses 
and immunological defence system129. However, due to the presence of several 
unpaired electrons, most of them are highly charged species, and a severe increase 
in their cellular level leads to “oxidative stress"; often result in irreversible oxidative 
damage causing cellular alterations, mutations and death130, 131. Our bodies natural 
defence response to high cellular ROS levels is to deploy special enzymes called 
"antioxidants" [such as, superoxide dismutase (SOD), catalase, glutathione 
peroxidase (GPx), glutathione (GSH),trace amounts of coenzyme Q, etc.], that 
represses the reactivity of ROS to lower levels and establish cellular redox 
homeostasis132, 133. Mounting amount of studies have found that most of the cancer 
cells exhibit increased aerobic glycolysis known as the Warburg effect, the discovery 
of which has given rise to new research interest towards the development of novel 
ROS- mediated therapeutic strategies134, 135. Cancer cells found in advanced tumours 
frequently show high oxidative state environments giving rise to a “vicious cycle". 
Generally, in the homeostatic state, ROS species activates wild-type p-53 protein in 
healthy cells that trigger stress responses and repairs the DNA from ROS-mediated 
damage. However, in cancer cells with defective p53, ROS mediated damaged DNA 
starts to accumulate which results in loss of function of p53. With ROS mediated DNA 
mutations and lack of deletions, the accumulation of damaged DNA propagates 
genomic instability, activation of oncogenes, metabolic dysfunction causing more DNA 
damage and contributing to cancer spread127, 136. Constant exposure to intrinsic 
oxidative stress may exert adaptive mechanisms to counteract the potential toxic 
effects of elevated ROS levels and to promote cancer cell survival. Thus, 
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Chemotherapeutics, especially, ROS generating agents alone are not sufficient to kill 
cancer cells. To maximise the ROS mediated therapeutic strategy; it is possible to 
apply antioxidant agents to have an additive or synergistic effect in cancer 
therapeutics.  
Endogenous and dietary antioxidants such as Vitamin C and E have been extensively 
investigated for its anticancer and antitumor properties and has shown modest clinical 
significance1-3. However, these antioxidants are limited by its poor selectivity for 
radical eradication, limited stoichiometric capacity, and dependence on detoxifying 
molecules14. Recent preclinical studies have demonstrated carbon nanomaterials 
such as single-walled and multi-walled carbon nanotubes, graphene, fullerenes, 
carbon clusters, carbon dots, etc. exhibit superior antioxidant properties than those of 
dietary antioxidants and it’s an affinity towards cellular uptake 14 12, 13. Their antioxidant 
properties have shown impressive results in not only ROS generated diseases such 
as inflammation, arthritis; neuro-generative diseases, cancer etc.133, 137-139; but also 
showed promising performance in recovery and restoration in patients who suffered 
traumatic brain injury12. However, among the various carbon particles utilized for 
biomedical applications, mesoporous carbon nanomaterials hold a more significant 
promise as it has a carbonaceous composition with high porosity, biocompatibility, 
chemical inertness, cellular affinity, which are highly desirable traits for therapeutics 
strategies2, 36. Moreover, owing to its physicochemical properties, biocompatibility and 
its cellular affinity, it readily interacts with ROS species (hydroxyl radicals) in the cells 
and displays ROS scavenging activity, which has never been reported in any other 
carbon nanoparticles. Thus, the most intriguing property of MCHS lies in its antioxidant 
property in its pristine form, which can be enhanced by changing its carbonization 
temperature. This property has never been observed in any other contemporary 
carbon nanoparticles. Herein, for the first time, we report the antioxidant property of 
mesoporous carbon hollow spheres (MCHS) optimized by the carbonizing temperature 
that assists it to have a hydroxyl scavenging property along with high cellular affinity 
and high biocompatibility without the need to functionalize. We further tested its 
antioxidant property compared to other contemporary pristine carbon nanoparticles 
such as carbon nanotubes and reduced graphene oxide in cancer cell line HCT-116. 
Hence, using optimized MCHS alone may function as effective antioxidants and have 
sufficient capacity for radical eradication to be used therapeutically during periods of 
excessive ROS generation.  
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Fig 5.1 Schematic representation of antioxidant MCHS-900 having ROS scavenging property. 
  5.2. Materials Specifications:  
 MCHS-T were synthesised and carbonised according to the procedure described in 
Chapter 4.   Carbon nanotubes (CNT), >98% were purchased from Sigma-Aldrich, 
product#719803-25G. Reduced Graphene oxide (RGO) was borrowed from the Centre for 
Personalised Nanomedicine laboratory, AIBN, UQ synthesised by Dr Xiaodan Huang using 
established protocol140 which he fully characterised141. HCT-116 adherent cells were grown 
in DMEM media supplemented with 10 % Fetal Bovine Serum (FBS) and 1% Penicillin-
streptomycin (PS). For subculturing purposes, the cells were washed with sterile PBS 
solutions and trypsin (0.25 g L-1). The cells were attached to T75 flasks and incubated 
at 37 °C under 5% CO2 sterile environment.   
5.3. Experimental section 
5.3.1. Hydroxyl free radical scavenging assay by EPR 
spectroscopy 
The reactive oxygen species was monitored by electron plasma resonance (EPR, 
Elexsys E500 CW, Bruker) spectroscopy using the spin trapping technique. In this 
method the intensity  was measured, resulting  from the conversion of a trapping agent 
DMPO  to  DMPO-OH● adduct brought about the hydroxyl free radicals generated by 
Fenton reaction: 
Fe2+ + H2O2           OH● + OH + Fe3+ 
Hydroxyl free radicals were generated by adding 10 mM of H2O2 into a PBS buffer 
solution, pH 7.4, containing 250 mM of 5, 5-dimethyl-1-pyrroline-N-Oxide (DMPO, 
trapping agent) and 1 mM of FeSO4. 50 µL of the sample were measured and were 
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marked as positive control.  Later, to test the scavenging property of the carbon 
nanoparticles. 100 µg of the particles were added to the mixed solution similar to 
positive control and incubated at room temperature for 20 min. 50 µL of the solution 
was then transferred into the capillary tube for EPR analysis of the remaining hydroxyl 
free radicals. 
 5.3.2. Intracellular ROS measurement using a fluorescent 
microplate technique 
HCT 116 cells were seeded in 96 welled plates (Corning 96 Well, clear bottom, 
fluorescence-based Microplate) at a concentration of 3 x 104 cells and incubated for 
24 hours at 37°C in 5 % CO2 sterile environment. Then the media is removed and 
washed with 100µL of 1XPBS per well. Then a 10µM solution of tert-Butyl 
hydroperoxide (TBHP) was added to each well to emulate the oxidative stress 
environment in cells leaving control groups were incubated for an hour at 37°C in 5 % 
CO2 sterile environment. Then the MCHS samples carbonised at different 
temperatures (700˚C -1300 ˚ C) were added to each well at a concentration of 25µg/mL 
and incubated. Then the PBS is removed, and 25 µM of DCFH2-DA is added to each 
well. The cells were incubated for 45 minutes at 37°C in 5 % CO2 under dark 
conditions. Then dye solutions were removed, and the cells were again washed with 
1x PBS. Then 100 µL of the buffer solution is added to each well, and the plates were 
read in Tecan Plate Reader PRO 200, at an excitation wavelength at 485 nm and 
emission wavelength at 535 nm.  
5.3.3. Detection of ROS scavenging activity using 
fluorescence imaging 
HCT 116 cells were seeded in a 6-welled plate at a seeding concentration of 1.5x105 
on the surface of sterilised coverslips in DMEM media supplemented with 10 % Fetal 
Bovine Serum (FBS) and 1% Penicillin-streptomycin (PS). The cells were incubated 
for 24 hours at 37°C in 5 % CO2 sterile environment. 10 µM of TBHP (Tert-Butyl 
hydroperoxide, {TBHP), 70 % in H2O, was added to each well, and the cells were 
incubated for an hour at 37°C generating an intracellular environment of extreme 
oxidative stress.  One of the wells were left untreated with TBHP and were marked as 
the negative control. Then the carbon-scavenging agents were added to each well at 
a concentration of 25µg/mL leaving one of them as the positive control. The cells were 
incubated for 4 hours at 37°C in 5 % CO2 sterile environment. After the incubation 
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period, the media was removed, and the cells were washed with sterile 1xPBS twice. 
After that 25µM solution of DCFH2-DA (2′, 7′-dichlorodihydrofluorescein diacetate) 
were added to cells to stain them. The cells were incubated for 45 minutes at 37°C in 
5 % CO2 under dark conditions.  Then dye solution was removed, and the cells were 
again washed with 1x PBS twice. Then 500µL of 4% PFA (Paraformaldehyde) to each 
well and were incubated overnight at room temperature.  Again, the cells were washed 
with 1xPBS, and then the cells were observed under a bright field microscope with an 
excitation wavelength at 485nm and emission wavelength at 535nm. The cellular 
uptake was also quantified by flow cytometry analysis (FACS) using BD Accuri™ C6 
Plus. 
 5.3.4. Flow cytometry analysis to evaluate ROS 
scavenging activity 
HCT-116 cells were grown on 12-welled plates at a seeding concentration of 0.5 x 106. 
After overnight incubation at 37°C in 5 % CO2, the media was removed, and the cells 
were washed with sterile PBS. Then a 10µM solution of TBHP was prepared in a 
serum-free media and was added to each well to induce oxidative stress. The cells 
were incubated for an hour at 37°C in 5 % CO2, and the nanoparticles were added, 
and the cells were incubated for 12 hours. After that 25µM solution of DCFH2-DA (2′, 
7′-dichlorodihydrofluorescein diacetate) were added to cells to stain them. The cells 
were incubated for 45 minutes at 37°C in 5 % CO2 under dark conditions.  Then 
DCFH2-DA solutions were removed, and the cells were again washed with 1x PBS 
twice. The cells were washed thrice and trypsinised using (0.25 %) Trypsin-EDTA and 
incubated for 3 minutes at 37°C in 5 % CO2. The trypsinized samples were collected, 
centrifuged and washed with sterile PBS and resuspended in FACS Buffer (1 % BSA 
and EDTA  solution made in Ca2+ and Mg2+ free Phosphate buffer).  The samples were 
then analysed using “BD Accuri C6” flow cytometer. All the samples analysed were 
triplicated. 
5.3.5. Cellular uptake study of carbon-scavenging agents  
HCT116 cells were seeded in sterile glass coverslips placed in 6-welled plates at a 
density of 1.5 x105 cells per well and cultured for 24 hours in DMEM media at 37 °C in 
5 % CO2 sterile environment. Simultaneously, Rhodamine B (RhB) was loaded in the 
1 mg of carbon nanoparticles with an RhB feeding amount of 5µg/mL in PBS solution.  
The loading amount was measured by measuring the difference in UV-Vis absorbance 
of RhB in the solution before and after adding carbon-scavenging agents.  Then the 
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RhB loaded carbon-scavenging agents were added to the wells at a concentration of 
0.35 µg/mL of RhB, finalised from the loading amounts. Then the cells were incubated 
for 4 hours at 37 °C after which the media was removed, and the coverslips with 
attached cells were washed twice with PBS.  After washing the cells, 500 µL of 4 % 
w/w paraformaldehyde solution was added to each well to fix the cells followed by 
incubation overnight at room temperature.  Later, the coverslips were rewashed with 
PBS twice, and the coverslips were attached to the slides by adding DAPI stains and 
let it dry at room temperature. In the end, the cellular images were taken using a Zeiss 
LSM 710 META confocal microscope (Carl Zeiss, Thornwood, New York).  
5.3.6. Flow cytometry analysis to evaluate cellular uptake  
The cellular uptake of MCHS-900, CNT and RGO were estimated using flow cytometry 
analysis. Before the cellular study, 5µg of RhB was wholly absorbed in 1 mg of samples 
in 1.5 ml of PBS, washed and suspended in sterile PBS solution. HCT-116 cells were 
grown on 12-welled plates at a seeding concentration of 0.5 x 106. After overnight 
incubation at 37°C in 5 % CO2, the media was removed, and the cells were washed 
with sterile PBS.  Then 0.35 µg/mL of RhB loaded particles were added to each well. 
The cells were incubated for 4 hours at 37°C in 5 % CO2. The cells were washed thrice 
and trypsinized using (0.25 %) Trypsin-EDTA and incubated for 3 minutes at 37°C in 
5 % CO2. The trypsinized samples were collected, centrifuged and washed with sterile 
PBS and resuspended in 500µL of FACS Buffer (1 % BSA and EDTA  solution made 
in Ca2+ and Mg2+ free Phosphate buffer).  The samples were then analysed using “BD 
Accuri C6” flow cytometer. All the samples analysed were triplicated. 
5.4. Results and discussion: 
Hydroxyl radical (OH●) is the most abundantly found ROS in the human body, and 
we did a preliminary EPR analysis to investigate the OH● radical eliminating property 
of pristine MCHS modified with carbonization temperature, Fig.5.2 (A). We found 
that at 900˚C, MCHS’s scavenging activity of hydroxyl ions was enhanced, however 
further elevation of carbonization temperature diminished its scavenging influences.  
The EPR profiles of MCHS carbonised at different temperatures (700˚C -1300 ˚C) 
showed an interesting trend. At 700 ˚C, the percentage of hydroxyl radicals 
scavenged was close to ~65.00 %. As we carbonised MCHS at a higher 
temperature, the scavenging activity of MCHS was heightened, and the radical 
annihilation was close to ~74.00%. However, the trend didn’t linger for long, further 
increase in carbonization temperature the scavenging activity of MCHS kept 
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reducing where MCHS carbonised at 1100 ˚C, and 1300 ˚C reduced approximately 
~69.60 % and ~67.40 %, respectively.  From EPR analysis, we could found that 900 
˚C is the optimized temperature of carbonization for MCHS that has the ability to 
bring out the best hydroxyl scavenging property in pristine form.  Additionally, we 
conducted an EPR analysis of MCHS-900 compared to other carbon-scavenging 
agents in its pristine form as well, as shown in Fig. 5.3 (A). The EPR results revealed 
that in aqueous solutions RGO had a higher scavenging activity than CNT, where 
RGO reduced the OH● levels to ~30.4 % and CNT brought the levels down to ~17.4 
%.  Summarizing all the EPR analysis data, we could conclude that pristine MCHS-
900 carbonised at 900°C not only has an excellent scavenging ability than any other 
MCHS carbonised at other temperatures (700 °C -1300 °C) but also its still the best 
carbon scavenging agent in its pristine state than other popular carbon-based 
scavenging agents.  
 
  Fig 5.2 (A) Effect of MCHS carbonised at different temperatures on hydroxyl radicals generated by 
Fenton reaction. The number of radicals produced is proportional to the intensity of EPR signals(B) 
Intracellular ROS scavenged by MCHS carbonised at different temperatures in HCT-116 cells, ns, 
*p<0.05, **p<0.01, ***p<0.001. 
We proceeded further to investigate the intracellular hydroxyl radical annihilation 
ability of pristine MCHS and weather the carbonization temperature influences its 
ability to scavenge ROS intracellularly as it does extracellularly. As shown in Fig. 
5.2(B), the intracellular ROS scavenging activity changed as MCHS were modified 
at different carbonization temperature. We observed after cellular interaction of 
HCT-116 cells with MCHS-700, ~50.00 % of TBHP induced ROS were scavenged. 
As the temperature of carbonization was elevated, the amount of ROS scavenged 
was massively amplified by an average of 97.93 %. However, as the temperature of 
carbonization was increased further, the scavenging activity was affectedly 
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reversibly. MCHS-1100 showed a slight drop in the scavenging activity to an 
average of ~92.00 % whereas MCHS-1300 dropped even further to ~65.14%. Thus, 
we observed that MCHS carbonization temperature had the highest ROS 
scavenging prowess over any other carbonization temperature indicating the MCHS-
900 being the ideal candidate.  
Fig 5.3 (A) Effect of different carbon nanoparticles on hydroxyl radicals generated by Fenton reaction 
measured by the intensity of EPR signal (B) Intracellular ROS scavenged by different carbon 
nanoparticles in HCT-116 cells, ns, *p<0.05, **p<0.01, ***p<0.001. 
 
Fig.5.4 Bright field images of HCT-116 cells stained with DCFH2-DA (green fluorescence) after being 
incubated with tert-Butyl hydro peroxide and then treated with 25µg of carbon nanoparticles to detect 
their scavenging property (A) Positive control (B) CNT (C) RGO (D) MCHS-900 
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Fig 5.5 Confocal images of HCT-116 cells showing cellular uptake of carbon samples loaded with 
RhB with the same feeding amount of RhB determined from the loading capacity of the samples 
where (A)DAPI@Control PBS (B) PBS (C) DAPI combined with CNT@RhB (D)CNT@RhB (E)DAPI 
combined with MCHS-900@RhB (F)MCHS-900@rhB (G)DAPI combined with RGO@RhB (H) 
RGO@RhB. The scale bar is 2µm. 
 However, we wanted to investigate further how MCHS-900 in its pristine form 
compares to other carbon antioxidant agents are currently used as antioxidants, 
CNT and reduced graphene oxide. One of the most popular and engineered carbon 
allotrope C60 for potential biomedical application wasn’t added to study group as it’s 
a tendency to form strong aggregates in unmodified forms which weren’t suitable for 
the fair comparison of other carbon forms in their unmodified versions. 
 To make a relative investigation of the antioxidant property of MCHS-900 with other 
carbon antioxidant agents, we conducted a visual fluorescent imaging test to verify 
the difference in fluorescence of ROS reactive dye DCFH2-DA, where the intensity 
of the dye is proportional to the amount of ROS inside the cells. As shown in Fig. 5.4 
(A), a strong green fluorescence indicates a state of extreme oxidative stress induced 
by TBHP.  However, as shown in Fig. 5.4 (B), after incubating the cells stressed with 
high ROS levels with CNT, the fluorescence of the dye diminished indicating that 
some amount of ROS was successfully scavenged by CNT after its cellular 
interaction.  However,   the fluorescence coming from a cell that was subjected to 
RGO as antioxidant agents showed very little difference in the fluorescence, 
indicating the cellular interaction of pristine RGO is enormously less, Fig. 5.4 (C); 
thus; RGO is ineffective when it comes to scavenging ROS in pristine form.   
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Fig 5.6 Flow cytometry analysis of cellular uptake of different carbon uptake of different carbon 
samples loaded with RhB in HCT-116 after 4 hours of incubation, inset cellular uptake histogram; 
where, ns, *p<0.05, **p<0.01, ***p<0.001. 
When it comes to MCHS-900 however, the intensity of the green fluoresce was 
significantly diminished as can be seen in Fig.5.5 (D), indicating the high antioxidant 
property of pristine MCHS-900.  To quantify the amount of ROS species scavenged 
by the carbon agents, flow cytometry analysis was performed, as shown in Fig.5.3 
(B).  The FACS results revealed MCHS-900 scavenged an average of ~93.67% of 
ROS while CNT reduced the ROS levels by ~33.5% and merely ~10 % of ROS was 
reduced by RGO.  These results indicated that pristine MCHS-900 has superior 
antioxidant property and its very efficient ROS scavenging agent than other carbon-
scavenging agents.   
To understand the reason for the efficiency of MCHS-900 over other carbon agents, 
we conducted cellular uptake studies to observe the cellular interaction of MCHS-
900 compared to other carbon-scavenging agents by loading fluorescent dye in the 
samples, then feeding the cells and then observing them under confocal microscopy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
Pristine MCHS particles possess a relatively stronger capability to scavenge hydroxyl 
radicals compared with carbon nanotubes and reduced graphene oxide.  It exhibited 
a far excellent antioxidant property than other nanoparticles in their primary forms. In 
the cellular uptake study,  RhB dyes were loaded in each carbon-scavenging agents, 
and HCT-116 cells were exposed to equal amounts of RhB, and the number of carbon 
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nanoparticles was determined based on the loading capacity.  It was evident, as shown 
in Fig. 5.5 (A-H) that there was substantial red fluorescence of RhB coming from the 
cytosol of the cells exposed to MCHS-900 as compared to CNT and RGO indicated 
superior cellular uptake of  MCHS-900 than other samples.  Further, flow cytometric 
analysis confirmed the observation with a quantitative measure of the cellular 
interaction with the nanoparticles. The cellular uptake FACS histogram indicated the 
highest mean fluorescence is coming from cells having an interaction with MCHS-900 
compared to other samples. MCHS-900 showed an average of ~21.0 % positive cells; 
whereas, CNT had an average of merely ~2.77% positive cells and  RGO had only 
~1.03% of positive cells, as shown in Fig .5.6. These results suggest that MCHS-900  
are incredibly beneficial for cellular interaction and are internalized in large amounts 
that in turn exposes a large number of nanoparticles to the ROS species inside the 
cells causing higher scavenging efficiency than other carbon nanoparticles.  
5.4. Conclusions 
In summary, EPR analysis of pristine MCHS carbonised at different temperatures 
revealed MCHS-900 carbonised at 900˚C has remarkable ROS scavenging profile with 
an efficiency of 74 % reduction in OH●  in the aqueous environment.  Further 
comparative EPR analysis revealed that MCHS-900 is 3.2 times and 2.7 times more 
effective than CNT and RGO, respectively. The intracellular study revealed MCHS-
900 has the highest antioxidant activity in its pristine form among all the other MCHS 
samples carbonised at different temperatures; with ROS inhibition of 93.7 % as well 
as among other carbon-based antioxidant agents.  The intracellular ROS scavenging 
efficacy was also confirmed via confocal imaging and flow cytometry.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
Moreover, intracellularly, CNT  showed higher antioxidant activity than RGO, where 
CNT reduced TBHP induced oxidative stress in HCT-116 cells  by ~30.41 % whereas 
RGO reduced the levels by ~17.4 %;  which was a reverse trend in EPR analysis; 
indicating RGO having less cellular interaction than CNT (which was proven via cellular 
uptake study. The cellular uptake study revealed that MCHS-900 has the highest 
cellular uptake followed by CNT and then RGO.  The high antioxidant efficacy of 
MCHS-900 could be attributed to ultrahigh cellular uptake and good ROS scavenging 
capability that is vital insight for chemotherapeutic and biomedical studies. Also, It 
sheds light on the prominence of carbonization temperature in mesoporous carbon 
spheres that dictates it’s antioxidant capabilities.  
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Chapter 6 
Carbonisation 
temperature optimised 
Mesoporous Carbon 
Hollow Spheres 
nanocarriers for chemo-
photothermal therapy of 
cancer cells 
This chapter reports the photothermal conversion efficiency of MCHS-T nanocarriers 
influenced by carbonisation temperature. This property can be utilised for an effective 
combined therapy as the nanocarriers deliver the anti-cancer drug molecule 
intracellularly while the nanocarrier themselves generate heat from irradiated light 
creating a state of intracellular hyperthermia.  
77 
 
6.1. Introduction: 
Over the past few decades, there has been a steady growth in the development of 
chemotherapeutic practices.  Chemotherapeutic agents that are being used in clinical 
practices presently inhibit cancer/tumour growth by different mechanisms of action 
such as attacking the DNA, inhibiting nucleotide metabolism, suppression of 
microtubule function142. Yet, a single hitting chemotherapy approach can cause 
remissions due to the unrestricted cell cycle of cancer which may not inhibit the cancer 
growth completely. That’s why the concept of multi-hit modality and combination 
therapy is emerging. Usually, the stage and type of cancer often determine whether 
single therapy or combination therapy is needed. The rationale for combination 
chemotherapy is to use drugs that work by different mechanisms or in combination 
with radiation/photothermal therapy, thereby decreasing the likelihood that resistant 
cancer cells will develop. When drugs with different targeting methods are employed, 
we can achieve the highest efficiency of cancer eradication using drugs at its optimal 
dose, without intolerable side effects. 
 In light of the multi-hit concept, heat shock protein- 90 (Hsp90) has been considered 
as the “wonder drugs”142, 143. Hsp90 is a chaperone protein that assists other proteins 
in folding correctly, stabilising them against heat stress, and aiding in protein 
degradation. They are a class of chaperone proteins that are among the most highly 
expressed cellular proteins across all species144. As their name implies, heat shock 
proteins protect cells when stressed by elevated temperatures. They are found in 
heavy concentrations in cancer/tumour sites. That’s why Hsp90 is a promising target 
in cancer therapy. Preclinical and clinical evaluations target the Hsp90 using a variety 
of Hsp90 inhibitors that have shown the antitumor effect as a single agent and in 
combination with chemotherapy. Geldanamycin (GA), a naturally occurring antibiotic 
isolated from Streptomyces hygroscopicus was the first Hsp90 inhibitor tested for 
anticancer/antitumor properties. Although GA exhibited potent anti-cancer activities in 
preclinical in vivo studies, it was determined to have little clinical potential mostly due 
to its high hepatotoxicity145, 146. As a result, a search for GA derivatives that maintain 
similar anti-cancer activities but with better toxicological properties was encouraged to 
be pursued. Thus, 17-AAG (17-allylamino-17-desmethoxygeldanamycin; 
Tanespimycin) 146, 147 was synthesized as a safer option than GA.  It showed promising 
antitumor effects in Phase I 148, 149and Phase II 150, 151clinical trials.   
 However, several drawbacks of 17-AAG, such as low water-solubility, instability in 
solution, and low oral bioavailability may become an obstacle to further clinical 
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application 152, 153. Thus, nanocarrier systems can provide the right assistance to 
overcome the limitations and enhance their effect and bioavailability.  Among the 
numerous nanocarrier systems available, mesoporous carbon nanocarriers are the 
best choice for this purpose owing to the following reasons (i) low density, porous 
shells, accessible interior space, high surface area, large pore volume offers more 
significant advantage to load higher amounts of active drug/biomolecule28, 75 (ii) they 
are highly non-toxic and biocompatible  23, 154 (iii) they  have very intriguing optical and 
photothermal properties 155, 156which makes them ideal nanocarrier systems for 
combination therapy using chemotherapy and photothermal therapy for cancer/tumour 
ablation. In our work, we aim to enhance the performance of 17 AAG in chemotherapy 
using mesoporous carbon nanocarriers as delivery vehicles. We integrated 
mesoporous carbon hollow spheres (MCHS) as nanocarrier systems to deliver high 
amounts of 17 AAG in cancer cells (chemotherapy) while irradiating them to inflict 
photothermal therapy simultaneously in combination.  
As we know carbonization temperature plays a crucial role in the synthesis of MCHS-
T in determining the physiochemical performance of the nanocarriers; thus, we also 
tested the up-conversion efficiency of irradiated light into heat. Our theory is that more 
intracellularly available 17AAG will be, more the cancer cells will get susceptible to 
thermal damage by its mechanism of action. Simultaneously the up-conversion of 
temperature optimized MCHS will elevate the heat intracellularly causing a combined 
therapeutic effect having maximum cancer cell death by creating an intracellular 
environment of hyperthermia. Hence, using optimized MCHS may function as a 
chemo-photothermal agent at the same time.  
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Fig 6.1 Schematic representation of the multi-hit modality of photothermal therapy and chemotherapy 
for a tumour and cancer cell ablation. 
  6.2. Materials Specifications:  
 MCHS-T were synthesized and carbonized according to the procedure described in 
Chapter 4. Cells were cultured in DMEM (Dulbecco's Modified Eagle Medium) with 
high glucose, L-glutamine and phenol Red as additives. DMEM were supplemented 
with 10 % Fetal Bovine Serum (FBS) and (1%), penicillin-streptomycin (10,000 U mL-
1). For subculturing purposes, the cells were washed with sterile PBS solutions and 
trypsin (0.25 g L-1). The cells were attached to T75 flasks and incubated at 37 °C under 
5% CO2 sterile environment.  For MTT assay, thiazolyl blue tetrazolium bromide (98%) 
was purchased from Sigma-Aldrich. UV irradiation was conducted using ML-3500 
Series, MAXIMA™ Ultra-High Intensity UV-A Lamp that utilises micro discharge light 
(MDL) technology with a spot reflector has a nominal steady-state UV-A intensity 
of 50,000 μW/cm2 at 240 V, 15 inches (38 cm). 
6.3. Characterization: 
UV-Vis characterizations were done using TECAN Infinite® 200 PRO microplate 
reader.  The optical properties of the nanoparticles were analysed using UV-2450 
Shimadzu Spectrophotometer.  
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6.4. Experimental section: 
6.4.1. UV-Vis Spectral analysis and photothermal test 
To test the spectral absorbance behaviour of MCHS-T, UV-Vis spectrophotometric 
analysis was conducted. The samples were prepared by making 1mg/mL solutions in 
PBS and thoroughly dispersing them by exposing them to ultra-sonication for 5 min. 
Then 50 µg/mL solution of MCHS-T were prepared and analysed under spectrometer 
baselining PBS. The photothermal tests were conducted to measure the ability of 
nanoparticle to convert incident light into heat. Two different concentrations of the 
particles (75 µg/mL and 200 µg/mL) were prepared and suspended in PBS solutions 
and were ultrasonicated for 10 min to achieve even distribution of nanoparticles in 
PBS.  After that, the  MCHS-T  solutions were irradiated for 3 minutes by a UV light 
source enclosed in a dark box. The temperature changes were detected using a digital 
thermometer to detect the temperature changes. 
6.4.1. Loading and release study: 
 For the loading test, first the active molecule “Tanespimycin (17-N-allylamino-17-
demethoxygeldanamycin, 17-AAG) “was dissolved in DMSO (Dimethyl sulfoxide) 
making a concentrated suspension of 5 µg/mL concentration designated as the stock 
solution.  A measured amount of the stock solution was dissolved in sterile phosphate 
buffer to make 125 ng/mL of solution (Solution A).  Then 100 µL of solution A was 
added to 1mg of MCHS-T samples in Eppendorf tubes, and the final suspensions were 
ultrasonicated for 10 min in an ultrasonicator bath while maintaining the water 
temperature at 4°C. Then the sample tubes were rotated in tube rotor for 24 hours in 
a cold room (in 4°C temperature) in complete darkness. The samples were retrieved 
and then centrifuged at 15000 rpm for 10 min.  In the end, the supernatant was 
separated and observed under NanoDrop UV- Vis spectrometer at 335 nm.   
To study the release of 17 AAG from MCHS-T, the drug-loaded particles were 
dispersed in 1 mL of buffer at pH 7.4 in Eppendorf tube. The tubes were placed in a 
dark room with 150 rpm at 37°C. At the predetermined time intervals, the nanomaterials 
solution was centrifuged at 13000 rpm for 10 min, and the supernatant was withdrawn. 
Then 50µL of the suspension was withdrawn for analysis and replaced by an equal 
amount of fresh PBS, and then the concentrations of the released drug were analysed 
at those predetermined time intervals as cumulative release amounts. 
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6.4.2. Chemo-photothermal therapy cell viability test using 
MTT assay 
The cell viability test was carried out by MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-
Diphenyltetrazolium Bromide) assay. Cellular toxicity of MCHS-T was tested by 
exposing MCF 7 cells with 17AAG loaded MCHS-T, incubating for a required period, 
irradiating it with UV irradiation for 3 min and measuring the absorbance of added MTT 
solution under UV-Vis spectrophotometer. MCF 7 cells were seeded in 24-well plate 
at a density of 0.05 x 106 cells/well. Then the cells were incubated for 24 hours at 37 
°C in 5 % CO2 sterile environment for the cells to attach to the plate surface. After the 
24 hours incubation, the cells were treated with an aqueous suspension of MCHS-T  
loaded with 17AAG, where the final concentrations of the loaded 17AAG were 12.5 ng 
mL-1.  Then the cells were incubated overnight for the cells to uptake the MCHS-T 
loaded with 17 AAG.  After that, the cells were irradiated with high-intensity UV light 
for 3 min.  Then the media was removed and washed with sterile PBS solution. Then 
1mL of 10 % MTT solution was added to each well, and the cells were incubated at 37 
°C for 4 hours.   After the incubation, the solution was removed, and 500 µL of DMSO 
was added to each well and shaken in Microtiter/PCR Plate Shaker for 15 minutes. 
The absorbance of the resultant formazan was measured in UV-Vis 
spectrophotometer at 570 nm. The following formula was applied to calculate the cell 
survival rate: 
𝑪𝒆𝒍𝒍 𝑽𝒊𝒂𝒃𝒊𝒍𝒊𝒕𝒚 (%) =
(𝒎𝒆𝒂𝒏 𝒂𝒃𝒔. 𝒐𝒇 𝒕𝒓𝒆𝒂𝒕𝒆𝒅 𝒈𝒓𝒐𝒖𝒑)
(𝒎𝒆𝒂𝒏 𝒂𝒃𝒔. 𝒐𝒇 𝒄𝒐𝒏𝒕𝒓𝒐𝒍 𝒈𝒓𝒐𝒖𝒑)
 𝑿 𝟏𝟎𝟎 
6.4.3. Biocompatibility using MTT assay 
Biocompatibility of the nanoparticles was also tested using MTT assay. Varied 
concentrations of MCHS-T were suspended in sterile PBS solutions and ultrasonicated 
for 10 minutes for even distribution in PBS. MCF 7 cells were seeded in 24-well plate 
at a density of 0.05 x 106 cells/well. Then the cells were incubated for 24 hours at 37 
°C in 5 % CO2 sterile environment for the cells to attach to the plate surface. 
Concentrations of 10 µg/mL, 20 µg/mL, 40 µg/mL, 60 µg/mL, 80 µg/mL, 100 µg/mL, 
200 µg/mL of MCHS-T were added to cells and further incubated for 24 hours. Then 
the media was removed and 1mL of 10 % MTT solution was added to each well, and 
the cells were incubated with at 37 °C for 4 hours which the solution was removed, 
and 500 µL of DMSO was added to each well and shaken in Microtiter/PCR Plate 
Shaker for 15 minutes. The absorbance of the resultant formazan was measured in 
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UV-Vis spectrophotometer at 570 nm. The cell survival was calculated using the cell 
viability formula mentioned above.  
6.5. Result and Discussion: 
 To test the feasibility of 17 AAG@MCHS-T as photothermal agents, we chose a UV 
light source to irradiate the particles, and we irradiated them for 3 minutes interval.  
 
Fig 6.2 Photothermal heating graph of MCHS-T at different concentrations of 75 µg/ml and 200 µg/mL 
after UV-A irradiation for 3 min. 
For this test, two different concentrations of MCHS-T were prepared as shown in Fig 
6.2. Before irradiation, the temperature of all the nanoparticles suspension groups 
including the control group was measured, and all were detected to be an average of 
19.8°C. When the control group PBS buffer was irradiated, no changes were observed 
in the temperature before and after irradiation. After adding 75 µg/mL of MCHS-500, 
the temperature of the suspension increased by the mark of ~ Δ 8.3°C. We observed, 
the higher the MCHS-T were carbonised during the synthesis process, the ability of 
photothermal conversion was also higher.  MCHS-(700, 900, and 1100) were able to 
increase the temperature to 29.7°C, 35.2 °C and 33.6°C respectively. When the 
concentration of MCHS-T was increased to 200 µg/mL, the photothermal conversion 
improved as well.  It was noted that MCHS-900 and MCHS-1100 reached over 40°C 
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which is considered to be the temperature of clinical significance. The aim of 
photothermal therapy is usually to reach the temperature of clinical significance to 
create an environment of hyperthermia inside tumour microenvironment157.  The 
primary reason for the thermal conversion property might be attributed to the carbon 
content and carbon crystallinity in nanomaterials158. Carbonising nanoparticles to 
higher temperatures enhance the carbon crystallinity and carbon-carbon linkage that 
helps with the thermal generation and conduction.  In this challenge, MCHS-900 
emerged as a clear winner as it has high aqueous stability along with desired carbon 
features for photothermal conversion.  When the temperature reaches higher than 
900°C, the aqueous stability of the nanoparticles is compromised which limits its 
clinical use.  
 
Fig 6.3 UV-Vis spectral analysis of MCHS-T in PBS buffer solution at pH 7.4. 
The efficiency of photothermal conversion can be clarified by the ability of MCHS-T to 
absorb light. To test the photo-absorption of nanoparticles UV-Vis spectrum was 
recorded. We detected the UV-Vis spectra of MCHS-500 to 1100 in PBS in the same 
concentration using PBS as a baseline. As shown in Fig 6.3, MCHS-900 demonstrated 
a characteristic sharp absorption peak at 223 nm. Meanwhile, MCHS-500 and MCHS-
700 didn’t display similar peaks in that spectral range.  MCHS-1100 showed peaks 
around 285nm -300 nm which indicates that M CHS-900 has better UV- A light 
absorption capacity than MCHS-1100. The high photoabsorption of MCHS-900 can 
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explain the high photoconversion of UV-A irradiated light into thermal energy ability 
demonstrated the best photothermal conversion efficiency among all MCHS-T. 
 
Fig 6.4.  (A) The loading efficiency of 17 AAG in MCHS-T (B) the release profile of MCHS-T, ns p> 0.05, 
*p<0.05, **p<0.01, ***p<0.001. 
 The structural features of MCHS-T are highly desirable for drug delivery owing to large 
surface area and mesopores. However, these advantageous features are dictated by 
the temperature at which the nanoparticle templates are carbonised. To evaluate the 
loading performance of MCHS-T, 125 ng mL-1 of 17 AAG (Tanespimycin) were mixed 
with nanoparticles in PBS buffer solution at neutral pH. Fig 6.4 shows MCHS-500 had 
the lowest loading capacity while MCHS-900 had the highest loading with a mean of 
~65 ng of 17 AAG. The existence of hydrophobic behaviour and high dispersibility 
made 17 AAG loading very reasonable. With the lower carbonisation temperature like 
500°C and 700°C, the hydrophobic nature of the nanoparticles are compromised which 
lowers the loading capacity of the particles.  However, MCHS-1100 had a lower loading 
amount than MCHS-900, probably due to the poor aqueous distribution and 
aggregation in PBS. The release profile of MCHS-T showed a clear trend as shown in 
Fig 6.4(B). The in-situ release of 17AAG was evaluated in a PBS buffer solution at 
37°C for more than 6 hours.  These first 6 hours are essential for the cells to uptake 
the nanocarriers to release the HSP90 inhibitor intracellularly for the inactivation of 
heat shock protein categorised under chemotherapy.   We observed that the 
temperature at which MCHS was carbonised is directly proportional to the percentage 
% release of 17 AAG.  The sustained release of 17 AAG was more in MCHS 
carbonised at a higher temperature than lower temperature. As previously 
demonstrated, the hydrophobicity of the nanocarriers enhances along with 
carbonisation temperature. Thus the hydrophobic interaction between the drug 
molecules and the nanocarriers are higher attributing to more sustained release. We 
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observed that while MCHS carbonised at lower temperature release an average of 
31% of the drug by the 6th hour, MCHS-900 released 29.5% while MCHS-1100 
released only 22%. While usually cancer therapeutic drug delivery, sustained release 
of the drug molecule is a desired trait, however, in combination therapy, the release 
should be enough to elicit a desired chemotherapeutic response so that the 
photothermal effect can kick in a synergistic effect. This enhanced effect was tested 
further in cell viability tests.  
Fig 6.5 (A) Dosage-dependent cell viability of MCF 7 cells treated with bare testing the biocompatibility 
of MCHS-T after 24 hours incubation (B) Cell viability of MCF 7 after combination therapy by exposing 
them to pure 17 AAG, only MCHS-T and 17 AAG loaded in MCHS-T and after irradiation with UV light 
irradiation for 3 minutes; ns p> 0.05, *p<0.05, **p<0.01, ***p<0.001. 
  
The in-vitro cytotoxicity of MCHS-T of MCF 7 cells was investigated by MTT assay. 
Fig 6.5 (A) showed no obvious cytotoxicity to MCF 7cells from a concentration of 10-
200 µg of MCHS- T. We could observe MCHS-700, 900 and 1100 had very low 
influence in the concentration of the cells. However, MCHS-500 showed fairly high 
toxicity where the toxicity was proportional to the concentration of the nanoparticles. 
The display of higher toxicity with low carbonisation temperature may be attributed to 
cytotoxicity brought about by the residual polymer in the carbon framework in MCHS-
500 which are absent in MCHS carbonised at a higher temperature. 
  MTT analysis was also used to test the cell viability of MCF 7 cells after combination 
therapy. After adding 12.5 ng of drug molecule combined with irradiation, there wasn’t 
any significant decrease in cancer cell concentration. This may be due to the inability 
of the ultra-sensitive drug molecule to penetrate the cell membrane.  However, when 
bare particles were irradiated with UV irradiation, MCHS-900 showed inhibition of cells 
86 
 
of about 75% mean, owing to its high photoconversion efficiency, previously observed 
in the photothermal test.  MCHS-900 in itself was able to create a state of hyperthermia 
in the cancer cells owing to its high cellular uptake and high photoconversion 
efficiency. MCHS-1100 wasn’t able to create similar effects due to limited cellular 
uptake. MCHS-500 and MCHS-700, on the other hand, displayed low to moderate cell 
inhibition. However, when MCHS-T was combined with chemotherapy, the cellular 
inhibition of MCF 7 cells was enhanced due to its dual targeting. After the cells were 
exposed to 17 AAG loaded MCHS-T, 17AAG were escorted and released 
intracellularly making the cells sensitive to thermal damage. Thus, after irradiation the 
state of hyperthermia caused the cells to die off.  This combination therapy was most 
significant in MCHS-900 loaded with 17AAG as shown in Fig 6.5 (B).  Because of the 
high cellular uptake efficiency of MCHS-900, 17 AAG was escorted inside the cell very 
effectively which allowed it to act on the chaperone protein aka. HSP 90 proteins of 
the cancer cells forcing them to become inactive. This caused the cancer cells unable 
to defend or repair itself from the heat produced intracellularly causing significant 
damage to cancer cells. 
6.6. Conclusion: 
In summary, all the above test demonstrated that the photoconversion efficiency of 
mesoporous carbon nanoparticles could be tuned by tuning its carbonisation 
temperature. MCHS-900 showed the most efficient photoconversion ability where 200 
µg of the nanoparticles were able to raise the temperature to clinical significance. The 
photothermal test revealed that MCHS-900 and MCHS-1100 had high 
photoconversion of irradiated UV light that MCHS-500 or MCHS-700. Not only that 
MCHS-900, owing to its hydrophobicity, mesoporosity and high surface area was able 
to load the highest amount of drug 17 AAG along with a sustained release. Moreover, 
MCHS-900 also showed high biocompatibility and high cellular toxicity when combined 
with a drug molecule and used in combination with photothermal therapy. 
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Chapter 7 
Conclusion and Outlook 
The research that I have accomplished during my PhD is presented in this dissertation 
provides a guide to optimise multi-functional mesoporous carbon nanocarriers by 
controlling the carbonisation temperature during the fabrication process using a hard 
templating method. This dissertation discussed in details how the carbonisation 
temperature would influence the behaviour and characteristics of the nanocarriers to 
display its highest biomedical performance.  Currently, mesoporous carbon 
nanocarriers are being extensively investigated for bio applications especially in 
cancer therapeutics as it possesses several advantageous qualities than other carbon-
based nanocarrier systems such as the open porous framework for higher 
drug/biomolecule loading, sustained release pattern, high biocompatibility, high 
cellular uptake, faster endosomal escape.  Carbonisation temperature plays a key role 
in the development of the advantageous features of mesoporous carbon nanocarriers. 
Setting up the carbonisation temperature is crucial during the fabrication process as it 
determines the morphology, carbon content, crystallinity, carbon-carbon bonding, 
hydrophobicity etc., as the 3D carbon framework is being formed in a controlled 
environment. These physicochemical properties determine its multifunctional ability 
such as therapeutic drug delivery efficiency, free radical scavenging property or 
photothermal conversion efficiency.  
7.1. Conclusions: 
 7.1.1. In the first project, Chapter 4, we dived into the first functionality of the 
nanocarrier system, i.e. therapeutic drug delivery. For this project, mesoporous carbon 
nanocarriers MCHS-T were fabricated using silica hard templating method, where the 
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resorcinol-formaldehyde polymer was used as a carbon precursor source. The 
polymer-silica matrix were carbonised at various temperatures from 500°C (MCHS-
500), 700°C (MCHS-700), 900°C (MCHS-900) and 1100°C (MCHS-1100) to 
investigate the physicochemical changes in the nanocarriers synthesized followed by 
the evaluation of its therapeutic delivery of therapeutic protein performance in cancer 
cells.   MCHS-500 showed an aggregated, non-uniform and partially concaved 
spherical morphology. Other nanocarriers showed spherical morphologies with 
uniform particle sizes of  170 nm in diameter. Out of all the nanocarrier systems, 
MCHS-900 emerged as the nanocarrier with the with high aqueous distribution with 
0.1 PDI, high carbon content (84.2 %), high surface area, high loading capacity of 
RNase A protein, better hydrophobicity and sustained release of the protein. Moreover, 
the nanocarriers displayed efficient cellular activity such as uptake and quicker 
endosomal escape to carry and release the protein intracellularly the most efficient 
way possible compared to other nanocarrier systems.  This resulted 74.4% of cell 
inhibited by MCHS-900@RNase A at the dosage of 50 µg mL-1 in first 24-hour 
incubation while after 48-hour incubation, 93.9% of the cells died indicating potent 
anticancer activity.  It was concluded that temperature lower than 900°C carbonisation 
temperature suffers from poor physicochemical properties that hinder its biological 
effectiveness.  While carbonisation temperature higher than 900 °C  suffers from lower 
colloidal stability and poor cellular uptake that impedes their full potential as a 
nanocarrier.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
7.1.2. The major contribution of this work is the discovery of the antioxidant properties 
of this nanocarrier system which is the second functionality of MCHS dictated by the 
carbonisation temperature. In this project, we found that MCHS-900 has high free 
radical scavenging activity with an efficiency of 74 % reduction in OH●  in the aqueous 
environment, higher than any other MCHS-T. When compared with other popular 
nanocarrier systems such as CNT and RGO, it showed 3.2 and 2.7 times higher 
antioxidant activity respectively. Moreover, MCHS-900 can reduce the intracellular 
ROS levels by 93.7 % of the oxidatively stressed cells. Utilising MCHS-900 might be 
an effective way to reduce the cellular oxidative stress in cells that can create and 
propagate cancer or tumour formation (details can be referred to in Chapter 5). 
7.1.3.  Utilizing the knowledge gathered in the previous project on the physicochemical 
changes brought about by the carbonisation temperature, we proceeded to test the 
photoconversion ability of MCHS-T for its application in combination cancer therapy.  
MCHS-900 showed high photoconversion ability by reaching 43°C (clinical threshold 
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>40°C ) after UV irradiation.  17 AAG,  a heat shock chaperone protein inhibitor, was 
loaded in MCHS-900 which suffers from low bioavailability on its own.  We then applied 
a combination of 17AAG@MCHS-900 incubated with MCF-7 breast cancer cells and 
irradiated with UV light showed ~86% reduction in cells detected by MTT assay. MCHS 
carbonised at lower temperature didn’t have much photoconversion efficiency while 
MCHS carbonised at higher temperature although showed good photoconversion 
efficiency, had lower cytotoxicity owing to lower cellular interaction.We  concluded that 
carbonisation temperature also influences the photothermal capabilities of 
nanocarriers of converting light into heat that might be a useful tool when applied in 
photothermal or combination therapy 
 Thus,   this PhD dissertation concludes that 900°C is the optimised temperature at 
which the mesoporous carbon nanocarriers should be carbonised during the 
fabrication process to achieve the best biomedical functionality.  
 7.2. Recommendations for future work 
This work introduced the dynamics that come into play when it comes to the influence 
of carbonisation temperature during fabrication of mesoporous carbon nanocarriers 
and the changes it brings in its multifunctional bioapplications. However, there is still 
room to do a more elaborate investigation of ways to improve the efficiency of 
mesoporous carbon nanocarriers. The versatility of MCHS allows them to be applied 
in different ways such as drug delivery systems, ROS scavengers and photothermal 
agents which may help combat cancer /tumour growth, propagation and malignancies. 
 In chapter 4, we focussed our attention on the delivery performance of the 
mesoporous carbon nanocarriers.  Carbonising MCHS at the optimised temperature 
helped us deliver fragile therapeutic protein in large amounts intracellularly to achieve 
cancer cell inhibition. As a result, we achieved high anti-cancer effect from more safer 
and potent therapeutic protein than conventional chemotherapy that results in 
numerous side effects.  
 In chapter 5,  we have shown the outstanding ability of MCHS-900 to scavenge free 
radicals that are highly detrimental and can cause major illnesses. High levels of 
intracellular ROS are the primary reason for many grave illnesses including cancer. 
Overextended exposure of ROS has shown to create new cancer cells and help in its 
growth. Using potent antioxidant agents such as MCHS might be a solution to this 
challenge as it effectively scavenges intracellular free radicals more effectively than 
any other carbon nanocarrier agent or conventional antioxidants.  More investigation 
99 
 
might lead to more breakthroughs related to the possibilities of utilising its antioxidant 
properties to only cancer but also other grave illnesses. 
In the final project, chapter 6, we were able to use MCHS as a photothermal agent as 
well as a chemotherapy nanocarrier. The versatility of the nanocarrier allowed us to 
successfully use it as a combination therapy in breast cancer cells.  MCHS-900 
showed useful photothermal of irradiated light into heat which reached to clinal 
significance while delivering low bioavailable and sensitive 17 AAG HSP90 inhibitor 
causing significant cellular inhibition.   Unfortunately, due to time constraints,  we 
couldn’t investigate the project further. There is still room for more investigation such 
as in- vivo studies that can show the nanocarrier systems inhibit the growth or shrink 
the localised tumour with this combination therapy and mark the effectiveness of this 
therapy.  
 Through this PhD dissertation, I hope we were able to shed some light into the 
optimisation process of mesoporous carbon nanocarrier systems and its 
multifunctionality aspect and wish to see it transition from a proof of concept to clinical 
relevance and practice. 
 
 
 
 
 
 
